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Abstract 
This thesis examines breast cancer incidence and stage at diagnosis in Ontarians with 
and without intellectual disabilities.  The objectives were 1) To describe and compare 
the incidence of breast cancer in women with and without intellectual disabilities 
from 2000 to 2014; 2) To describe and compare breast cancer stage at diagnosis in 
women with and without intellectual disabilities from 2010-2014.   
Manuscript 1 (Incidence): Through a retrospective cohort methodology, breast 
cancer incidence in women with intellectual disabilities was found to be not 
significantly different from women without intellectual disabilities.   
Manuscript 2 (Stage):  A cross sectional study demonstrated women with 
intellectual disabilities were significantly more likely to be diagnosed at a later stage 
(II-IV) (odds ratio 1.6; 95%CI=1.03-2.48) when compared to women without 
intellectual disabilities. 
Conclusion:  The results of this study suggest women with intellectual disabilities 
have a comparable incidence of breast cancer to women without intellectual 
disabilities, but they may have an increased risk of being diagnosed at a later stage.   
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1.1 Introduction to Thesis 
1.1.1 Introduction 
 The introduction to the thesis provides important and relevant definitions and 
brief descriptions of relevant background and epidemiological information.  It also 
describes the theoretical framework and how it was applied in the present study and ends 
with a description of how the thesis was organized. 
1.1.2 Intellectual disabilities 
The Diagnostic and Statistical Manual of Mental Disorders (DSM) -5 defines 
intellectual disabilities (ID) as impairments in both general mental abilities and adaptive 
functioning (American Psychiatric Association, 2013).  Adaptive functioning is measured 
using standardized testing and clinical assessments in three main domains: conceptual, 
social and practical.  Conceptual functioning refers to skills in language, reading, writing, 
and math.  The social domain includes areas such as empathy, interpersonal 
communication and the ability to make and retain friends.  Lastly the practical domain 
refers to areas that center on self-management.  Symptoms must begin in the 
developmental period of life.  The severity of an intellectual disability can be categorized 
into four groups:  mild, moderate, severe and profound.  Most people with intellectual 
disabilities are diagnosed in the mild category (Maulik, Mascarenhas, Mathers, Dua & 
Saxena, 2011).    
In order to gauge an individual’s general mental abilities, intelligence quotient 
(IQ) tests can be administered to assess intellectual functioning.  A score of 70 or less 
indicates a limitation in intellectual functioning (American Psychiatric Association, 




2007; Tasman, Kay, Lieberman, First & Riba, 2015).  Some examples of conditions that 
are associated with ID are Down syndrome, fragile X syndrome and fetal alcohol 
syndrome (Tasman et al., 2015).   
1.1.3 Health disparities in people with ID 
Currently in Canada, people with ID make up approximately 0.78% of the total 
population (Lunsky, Klein-Geltink & Yates, 2013).  They represent a small subset of the 
general population that experiences a variety of disadvantages and higher levels of 
morbidity.   
Their life expectancy is shorter than people without ID, although it is increasing 
in a parallel fashion to those without ID (Bittles et al., 2002; Emerson & Baines, 2011; 
Kapell, et al., 1998; Perkins & Moran, 2010).  The study by Janicki, Dalton, Henderson 
& Davidson (1999) found that the average age of death in people with ID was 66.  Whilst 
the study by Patja, Iivanainen, Vesala, Oksanen & Ruoppila, 2000 found the median age 
at death in their study to be 62.  Although people with ID do die younger, people with ID, 
specifically those with mild ID are beginning to live as long as people without ID 
(Janicki et al., 1999; Patja et al., 2000).  As their life expectancy increases they are more 
likely to experience age-related health concerns or diseases, consistent with those found 
in people without ID including:  cardiovascular pathology, respiratory illnesses, 
gastrointestinal conditions and cancers (Emerson & Baines, 2011; Perkins & Moran, 
2010).    
Research has shown that people with ID are more likely to experience health 
problems than those without ID (Lunsky et al., 2013).  In a study conducted by van 




with ID in the Netherlands were 2.5 times more likely to be diagnosed with various 
health conditions than patients without ID.  Health conditions found in high rates include 
epilepsy, behavioural/mental health problems, fractures, skin conditions, poor oral health 
and respiratory disorders (Krahn, 2006).  They are also more likely than people without 
ID to be diagnosed with chronic conditions such as congestive heart failure, obstructive 
pulmonary disease, diabetes or asthma (Lunsky et al., 2013).  Overall, people with ID are 
more likely to have higher levels of morbidity when compared to people without ID 
(Lunsky et al., 2013).  The high morbidity levels and disadvantages faced by this sub 
population make them a priority group for further research aimed at addressing the 
disparities they experience. 
Multiple studies have been conducted that report on the increased health problems 
and high morbidity experienced by people with ID (Lunsky et al., 2013; van Shrojenstein 
Lantman De Valk et al., 2000; Emerson & Baines, 2011).   Less research has been 
performed looking at specific health conditions such as cancer.  The cancer research in 
people with ID that does exist has used clinically based samples (e.g. hospitals) and very 
few are population based.  
1.1.4 Cancer in Canada 
It is estimated that nearly half of all Canadians will be diagnosed with cancer in 
their lifetime (Canadian Cancer Statistics, 2016).  Overall, the incidence of cancer has 
been increasing in Canada while cancer mortality has been decreasing.  Canada is 
currently faced with an aging population, and as a result, the number of people diagnosed 
with age-related diseases such as cancer is expected to increase (Canadian Cancer 




age of 50 and 44% diagnosed at 70 years of age and older in Canada in 2016 (Canadian 
Cancer Statistics, 2016).  Overall more males than females are diagnosed with cancer and 
it is the leading cause of death in Canada  (Canadian Cancer Statistics, 2016).  Measuring 
the cancer burden in Canada is essential for health policy and plays a pivotal role in 
guiding how decision-makers allocate health resources. 
1.1.5 Breast cancer incidence in Canada 
Breast cancer is a malignant disease that proliferates in breast tissue and can 
metastasize to other parts of the body.  Breast cancer can be broadly classified as either in 
situ or invasive (Bouhassira, 2015).   
Breast cancer incidence is determined by the number of new cases of disease 
diagnosed in a population over a specified period of time (Gordis, 2014).  Incidence data 
provides a measure of cancer burden in a population.  One in nine Canadian females are 
expected to be diagnosed with breast cancer in their lifetime and it is the leading cancer 
in women (Canadian Cancer Statistics, 2016).  Women between the ages of 50 -74 
represent the majority of people diagnosed with breast cancer (Cancer Care Ontario, 
2015a).  Along with other age-related diseases the number of people diagnosed with 
breast cancer is expected to increase.   
Women who participate in primary, secondary or tertiary preventive measures can 
reduce their risk of being diagnosed with breast cancer or improve their chance of 
receiving a diagnosis at a stage where they have an increased chance of survival.   
Primary prevention in breast cancer involves health promotion and risk reduction 
including lifestyle, diet modification and cessation of smoking (Al-Amri, 2005).  Breast 




disease when treatment is more effective (Youlden et al., 2012).  Tertiary prevention aims 
to improve breast cancer prognosis and quality of life through providing the best 
treatment methodologies after a diagnosis is made. 
1.1.6 Breast cancer risk factors 
Various factors contribute to an increased risk of being diagnosed with breast 
cancer.  Some risk factors of breast cancer include:  age, age at menarche and menopause, 
age at first pregnancy, family history, previous benign disease, body weight, hormone 
replacement therapy, the use of certain contraceptives and alcohol consumption 
(McPherson, Steel & Dixon, 2000).  Developing breast cancer is a result of multiple 
personal, familial, reproductive and lifestyle factors.  As women age, breast cancer risk 
increases, thus women in their 40s have a lower incidence of breast cancer in comparison 
to women over 50 (Elmore, Armstrong, Lehman & Fletcher, 2005; Humphrey, Helfand, 
Chan & Woolf, 2002; McPherson et al., 2000).  The start and ending of menarche plays a 
role as women who start menstruating early or have late menopause are at an increased 
risk of developing breast cancer (McPherson et al., 2000).  Women who do not have 
children or have their first child after 30 are at a greater risk of being diagnosed with 
breast cancer.  Family history also plays an important role, as having a first-degree 
relative diagnosed with breast cancer before the age of 50 increases an individual’s risk.  
In postmenopausal women, obesity is associated with increased breast cancer risk 
(Basen-Enquist & Chang, 2011).  Hormone replacement therapy increases the risk of 
breast cancer while also increasing breast density resulting in a reduction in the 




  Little research has been performed on women’s health issues in people with ID.  
Thus, it is unknown if having an ID is an independent contributor to the risk of being 
diagnosed with breast cancer. Women with ID experience a variety of risk factors that 
may make them more susceptible to breast cancer.  People with ID tend to lead sedentary 
lives and obesity is a common occurrence; prevalence estimates are approximately twice 
as high as those without an ID (Beiser & Stewart, 2005).  Women with ID experience 
menopause three to five years earlier than women without ID, which may play a 
protective role (Ouellette-Kuntz et al., 2005).  It is currently unknown why women with 
ID experience earlier menopause.  They are also more likely to be nulliparous, which is a 
risk factor for breast cancer (Emerson & Baines, 2011). 
1.1.7 Breast cancer screening 
Breast cancer screening is a secondary prevention tool that aims to diagnose 
breast cancer in the early stages of disease progression.  Mammography is considered the 
gold standard screening tool to detect breast cancer (Miller, 2001; Ontario Breast 
Screening Program, 2008).  It uses x-rays to detect and evaluate changes in the breasts 
and can help find small breast cancers while they are asymptomatic.  It is the most 
frequently used method to screen for breast cancer in women 50 -74 years of age and 
aims to reduce the incidence of advanced breast cancer (Cancer Care Ontario, 2015a).  
Other common modalities that can be used to screen for breast cancer include magnetic 
resonance imaging (MRI) and sonography.  MRI produces images through the 
combination of a strong magnetic field, radio waves and computer processing, while 




Alliance, n.d.).  Early detection is linked with an improved prognosis and a reduction in 
breast cancer mortality (Cancer Care Ontario, 2015a).   
While technological advancements have improved the sensitivity of 
mammography, controversies remain surrounding both its benefits and harms.  The 
potential benefit is avoiding advanced cancer.  The risks associated with mammography 
screening include false positive/negative results, over diagnosis and radiation-induced 
cancer.  Over diagnosis is defined as, “the detection of tumours at screening that might 
never have progressed to become symptomatic or life-threatening in the absence of 
screening” (Loberg, Lousdal & Kalager, 2015, p.2).  Currently all breast tumours are 
treated since non- and life-threatening tumours are indistinguishable (Loberg et al., 
2015).  A false positive mammogram occurs when a radiologist sees something abnormal 
that turns out to be benign upon further investigation.  False positive test results can cause 
women to have anxiety, worry about being diagnosed with breast cancer, and increase 
their perception of their breast cancer risk (DeFrank & Brewer, 2010).  These thoughts 
may in turn make some women hyper vigilant to continue with routine screening.  Other 
women experiencing a false positive may have a more negative experience and believe 
the tests are not very accurate, deterring them from future screening (DeFrank & Brewer, 
2010).   A false negative test occurs when breast cancer is present but was not detected in 
the mammogram.  False negative mammogram results may lead to delays in treatment 
and advanced clinical stage when diagnosed.  The risk of radiation-induced breast cancer 
is small in comparison to the expected mortality reduction associated with breast cancer 




1.1.8 Breast cancer diagnosis 
 A biopsy is performed when a suspicious area has been found either through a 
breast imaging modality or a physical exam.  A biopsy is the only definitive method to 
diagnose breast cancer.  Biopsies retrieve the suspicious sample from the breast, which is 
then microscopically analyzed (Compton et al., 2012).  Three types of biopsies can be 
performed to diagnose breast cancer: fine needle aspiration biopsy (FNAB), core biopsy 
and surgical biopsy (Canadian Cancer Society, 2016). 
1.1.9 Breast cancer staging 
Cancer is staged through the tumour, lymph nodes and metastasis (TNM) 
classification system.  It is a classification system that encompasses the characteristics of 
a tumour that define its behaviour and indicates the extent of disease (Compton et al, 
2012).  TNM breast cancer staging describes the size of the tumour, whether the cancer 
has spread to the lymph nodes and whether it has metastasized to other organs (Compton 
et al, 2012).  The stage of breast cancer can be categorized into five stages (See Appendix 









1.2 Theoretical Framework 
1.2.1 Model of Healthcare Disparities and Disability  
 The model of healthcare disparities and disability (MHDD) is an integrated model 
that takes into consideration the interactions between personal and environmental factors 
experienced by people with disabilities and the role they play in regards to health and 
health disparities (Meade, Mahmoudi & Lee, 2015).  This integrated model amalgamated 
various factors from the Aday and Andersen framework (Aday & Anderson, 1974), the 
Institute of Medicine (IOM) Model of Access to Healthcare Services (Institute of 
Medicine, 1993) and conceptualizations within the World Health Organization 
International Classification of Functioning (WHO-ICF) (World Health Organization, 
n.d.).  Its purpose was to enhance the understanding of disability and disparity in health 
and healthcare (Meade, Mahmoudi & Lee, 2015).    
The components of the MHDD retained from the WHO-ICF are body functions 
and structures, activities, participation, and environmental factors.  
When discussing disability in the context of health and healthcare disparities this 
model considers the role of individual factors, environmental factors, interactions 
(between individual and environmental factors) and health outcomes.  The relationship 
between characteristics in the environment and personal factors are hypothesized to be 
related to healthcare disparities for various populations (Meade, Mahmoudi & Lee, 
2015).  Personal factors relate to how race/ethnicity, gender, income, health literacy and 
disability influence health care.  Environmental factors include health systems, health 
policies, and social support (Meade, Mahmoudi & Lee, 2015).  The interaction of these 




environmental factors are linked and optimized can improvements be made to improve 
healthcare outcomes (Meade, Mahmoudi & Lee, 2015). 
1.2.2 Application of the Model of Healthcare Disparities and Disability   
 Disparities associated with breast cancer in women with ID have received very 
little attention.  Breast cancer policies and other related environmental factors designed 
for people without ID might not meet the needs of the population of people with ID.  The 
MHDD is a useful framework providing guidance for this thesis that aims to assess 
whether disparities related to breast cancer exist between women with and without ID 
while also incorporating personal and environmental factors.  This model recognizes the 
wealth of factors that affect healthcare quality and outcomes for people with ID (Meade, 
Mahmoudi & Lee, 2015).   
 The framework was helpful when selecting relevant variables especially as 
applied in manuscript 2.  The components of the MHDD that are the most relevant to my 
research are:  health status, body functions, activity, access to healthcare, environmental 

































Figure 1. Model of healthcare disparities and disability. Reprinted from “ The intersection of 
disability and healthcare disparities:  a conceptual framework,” by M.A.Meade, E. Mahmoudi 




























The model of healthcare disparities and disability showing the interaction between 
various factors and how they affect healthcare disparities 
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Health status refers to the health conditions experienced by the study participants 
and breast cancer is the focus of this thesis.  Secondary conditions that affected the health 
status of study participants were addressed in the breast cancer stage manuscript 
(manuscript 2) of this thesis. The health status of women with ID in manuscript 2 was 
also evaluated using a measure of morbidity and by determining the presence of diabetes.  
Body function/structure 
According to the WHO-ICF intellectual functions are a component of ‘body 
functions’ and are defined as “general mental functions, required to understand and 
constructively integrate the various mental functions, including all cognitive functions 
and their development over the life span” (WHO, 2001; WHO, n.d.).  This 
conceptualization is consistent with the definition of ID provided earlier by the American 
Psychiatric Association (see section 1.1.1) 
Activity 
 The WHO-ICF describes activities as the, “functioning at the level of the 
individual and the activity limitations they experience” (WHO, n.d.). 
In the context of breast cancer and ID, activity can refer to a variety of things.  
Adaptive behaviour, which is also part of the American Psychiatric Association’s 
definition of ID, can be considered an element of activity.  An example of an activity 
could be a person’s ability to communicate with health care providers the signs and 
symptoms of breast cancer that they may be experiencing.  People with ID frequently 
need extra support and health education, as they may not independently raise subtle 





 According to the WHO-ICF environmental factors pertain to, “ the physical, 
social and attitudinal environment in which people live and conduct their lives” (WHO, 
n.d.).  Specifically, environmental factors may include services, systems and policies that 
may contribute to health disparities and poorer health outcomes in people with ID.  Social 
and attitudinal factors may contribute to delay in diagnosis if people with ID are not 
educated by healthcare professionals about the importance of breast screening.  This 
includes people at all levels in the healthcare systems that are not adequately trained or 
skilled to work with people with ID.   
Access to Healthcare 
In the MHDD access to healthcare has five main components, affordability, 
availability, accessibility, accommodation and acceptability.  These factors may, 
“influence the extent to which an individual is able to maintain their health as well as 
future utilization of services” (Meade, Mahmoudi & Lee, 2015, p. 637).  Access to 
healthcare in the current study refers to the utilization of breast screening services (see 
manuscript 2).  Some factors that can affect breast screening utilization are the 
availability of locations offering breast screening services, accommodating equipment 
and the accessibility of locations.  A lack of participation may also be a result of a lack of 
education about the importance and benefits of breast screening.  
Personal Factors 
 This research addresses the role of personal factors and breast cancer.  






 The MHDD is a multi-faceted tool that embodies multiple frameworks of 
disability to create an all-encompassing framework that recognizes the importance of 
environmental and personal factors and how their roles and interactions can affect the 
health status of people with ID.  This framework will help guide the research about 
women with ID diagnosed with breast cancer highlighting any disparities in comparison 
to women without ID. 
 Using the MHDD has some disadvantages.  For instance, the model makes it 
difficult to distinguish between activity and participation because these concepts are not 
clearly defined.  Previous research has defined and used activity/participation concepts in 














1.3 Thesis organization 
 A manuscript format in compliance with the requirements of the Graduate 
Department of Health Sciences and the School of Graduate Studies at the University Of 
Ontario Institute Of Technology was used in this thesis.  The objectives of this thesis are 
addressed in manuscripts 1 and 2 and stand alone as manuscripts that will be submitted 
for journal publication.  For this reason the organization of this thesis will result in 
instances of repetition. 
 
Manuscript 1:  The first manuscript addresses the first objective to describe and 
compare breast cancer incidence in women with and without intellectual disabilities.  
 
Manuscript 2:  The second manuscript addresses the second objective using a subset of 
the cohort created in manuscript 1.  This manuscript describes and compares breast 














1.4 Objectives, Rationale & Thesis Methodology 
1.4.1 Objectives 
Manuscript 1 
1. The objectives for manuscript 1 are: 
a. Describe the incidence of breast cancer in women with and without 
intellectual disabilities 
b. Compare the incidence of breast cancer between women with and without 
intellectual disabilities 
Manuscript 2 
2. The objectives for manuscript 2 are: 
a. Describe the stage at breast cancer diagnosis in women with and without 
intellectual disabilities 
b.  Compare the stage at breast cancer diagnosis between women with and 
without intellectual disabilities 
1.4.2 Rationale 
As the life expectancy of people with ID continues to increase, they become more 
likely to develop age-related diseases such as cancer.  As they age, it is important to 
establish whether women with ID are at the same risk for developing breast cancer as 
women without ID.  
In addition to data on the incidence of breast cancer in women with ID, this 
research will provide data on their stage at breast cancer diagnosis.   
The small proportion of women with ID that I see in my professional practice as a 




performing mammograms on women with ID does present some challenges.  They are 
often very anxious, likely do to the lack of understanding of the procedure.  To reduce 
their anxiety and increase compliance, I spend a lot of time explaining the procedure and 
the importance of obtaining diagnostic quality images for the radiologist.  By using 
simple terms I aim to increase their understanding of the necessity of this procedure.  The 
methods I use to approach performing mammograms on women with ID have resulted in 
diagnostic quality exams.  Women with ID have often come with family members.  
Although the family is not allowed to stay in the room while the images are taken, they 
are usually very helpful when trying to explain the procedure to the women with ID.    
Although in my personal experience I have never had a women with ID refuse a 
mammogram either verbally or behaviourally, other mammographers have.  I hypothesize 
that this may occur if not enough time is spent communicating to the patient the steps in 
the procedure and the importance of the exam.  These experiences and observations have 
led me to think that it is possible that women with ID are not receiving timely access to 
breast cancer screening services and diagnostic procedures thus delaying diagnosis and 
treatment.  These clinical observations led me to see if any research had been performed 
on breast cancer screening, incidence and stage at diagnosis in this population.  My early 
literature search revealed that there was very little research on these topics.  In addition, 
upon discussions with my supervisor and other researchers in the area, it became clear 
that gaps exist in the literature that need to be addressed.   
The aim of this study was to gain a better understanding of the impact of breast 
cancer in this population and to identify disparities in breast cancer incidence and stage at 




with ID are at the same risk for being diagnosed with breast cancer, but are diagnosed at a 
later stage.  These findings are expected, as women with ID are less likely to participate 
in breast screening programs.   
Currently there is very limited information on breast cancer at the population level 
for people with ID in Canada.  There is a need for population-based research to 
understand the impact of breast cancer on women in with ID in Ontario in comparison to 
the women without ID.  This information is essential for government, policy makers and 
health professionals to make decisions based on Canadian evidence. The results of this 
















1.4.3 Thesis Methodology 
 Epidemiological approaches were employed to identify breast cancer incidence 
and stage at diagnosis in women with and without ID.   
For manuscript 1, a retrospective cohort study was used to identify the incidence 
of breast cancer in Ontario.  A cohort design was selected and administrative health 
databases were used to compare the incidence of breast cancer in two cohorts.  The first 
cohort consisted of women with ID and the second consisted of women without ID.  
Identifying the number of women with ID diagnosed with breast cancer conceptualized 
the burden breast cancer has on this population and whether it is different from that of 
women without ID.  An advantage of applying a retrospective cohort design was that it 
allowed the researcher to look back in time and report on cancer trends over a long 
period.  In addition, a retrospective cohort study was beneficial in studying women with 
ID as they represent such a small proportion of the population and administrative 
databases allowed for a relatively large sample to be identified.  As well a retrospective 
cohort study is both less expensive and time consuming as the databases used in the 
present study were already well established. 
     To report the breast cancer stage at diagnosis in manuscript 2, a retrospective 
cross-sectional study design was used.  This method was used to investigate whether 
there is a difference in breast cancer stage at diagnosis between women with and without 
ID.  The study consisted of two groups of women: one group consisted of women with ID 
diagnosed with breast cancer and the other consisted of women without ID diagnosed 
with breast cancer.  Once both groups were identified they were further classified into 




were used to identify women with breast cancer and their stage at diagnosis.  Health 
databases are both a cost effective and useful source of health information.   
 A disadvantage of both the cohort and cross-sectional study is the potential for 
misclassification bias.  There is a possibility in both studies that some women with ID 
































































2.1 Literature Review 
A narrative literature review was performed providing a synthesis of relevant 
reports and published studies.  The topics included in this literature review include:  
breast cancer incidence and stage at diagnosis in the general population, subpopulations 
and in people with ID.   
The primary objective of this literature review was to identify studies with 
methodologies applicable to the approaches used in both manuscripts.  The study 
descriptions in this review include a summary of the methods, results, strengths and 
limitations followed by a comment on why the study was useful.  In addition, Appendix 
C, Table 1 provides a brief summary of the studies included in the literature review. 
2.1.1 Incidence of breast cancer in the general population 
Breast cancer incidence provides information about the risk of developing the 
disease.  Updated information about breast cancer incidence is necessary for health policy 
implementation and decision-making.  Policy makers and public health workers use the 
data to assess population level needs for cancer management and prioritizing prevention 
strategies.  The following section reports on relevant population level research from 
developed countries using administrate databases. 
Canadian Cancer Statistics is a publication produced annually since 1987.  The 
aim of the publication is to provide information about the incidence, mortality and other 
measures of cancer burden.  The main data sources for the publication include the 
Canadian Cancer Registry (CCR), National Cancer Incidence Reporting System 
(NCIRS), Canadian Vital Statistics – Death Database (CVS: D), population life tables, 




registries, which collect clinical and demographic data on newly diagnosed cancer cases 
in their respective provinces.  From 2004 -2010, the incidence of breast cancer in Canada 
has stabilized following fluctuations since 1988 (Canadian Cancer Statistics, 2016).  The 
fluctuations noted prior to 2004 were in part attributed to a lead time bias related to 
increased mammographic screening and reductions in the use of hormone replacement 
therapy (HRT) (Canadian Cancer Statistics, 2016).   
A study by Kachuri, De, Ellison & Semenciw (2013) examined cancer incidence, 
mortality and survival trends in Canada from 1970 – 2007.  Incidence data was compiled 
from the CCR.  The study reported that the incidence of breast cancer in Canada rose at a 
rate of at 0.9% yearly between 1970 and 1998.  After that period the incidence began to 
decline at a rate of 0.7% yearly (Kachuri et al., 2013).  A limitation within this study is 
the completeness and accuracy of the data source, used to estimate incidence.  Registry 
data can vary across Canada resulting in an under or overestimation of disease rates.  This 
source is useful as it analyzed long-term trends using Canadian national databases to 
monitor cancer trends through a retrospective cohort.  This population-based approach 
can be applied to my research as it demonstrates how incidence can be calculated using 
data acquired from population-based databases in a Canadian setting.  
The Australian Institute of Health and Welfare (AIHW) uses administrative 
databases to provide an overview of the epidemiology of cancer in Australia.  The article 
by the Australian Institute of Health and Welfare (2013) focuses on the incidence of 
cancer, mortality and the burden of disease from 1991 to 2009.  Cancer data was acquired 
from the Australian Cancer Database (ACD), which holds information about cancer 




resident population data was based on the 2006 Census.  From 1991-1995 the incidence 
rate of breast cancer increased.  After this period the  incidence rates stabilized.        
Molinié et al. (2014) performed a retrospective cohort that detailed the incidence 
of breast cancer from 1990-2008 in France.  Nine population based French registries were 
used to report on breast cancer incidence in the population.  The incidence of breast 
cancer increased from 1990 – 2003.  Incidence began to stabilize after 2006.  The 
strength of the study is the registry data because the procedure for collecting data is 
standardized.  A limitation is that the regions and registries selected may not be 
representative of the entire French population. 
The study conducted by Kohler et al. (2015) was a population-based study that 
reported on cancer trends in the United States.  Population based incidence data was 
obtained from the North American Association of Central Cancer Registries and the 
National Program of Cancer Registries.  The study reported that breast cancer incidence 
remained relatively stable from 2002 -2011 (Kohler et al., 2015).  Breast cancers were 
generally diagnosed at a local stage and less likely to be diagnosed at a distant stage in all 
racial/ethnic groups.  Breast cancer at a local stage is solely confined to the breast as 
opposed to a distant stage where the cancer has metastasized to other parts of the body.  
A limitation of this study is that long-term trends (1992-2011) were reported based on 
only 13 state registries, which only represent 14% of the US population.  This study 
informs my methodological approach through its use of cohort methodology spanning 
multiple years reporting on incidence. 
After increasing for many decades due to a combination factors such as early 




general population in developed countries have found that, the incidence of breast cancer 
has stabilized in recent years (Canadian Cancer Statistics, 2016; Kohler et al., 2015; 
Molinié  et al., 2014).   Multiple factors may have contributed to this stabilization such as 
the reduced use of HRT and screening saturation whereby all prevalent cases have been 
discovered (Ferlay, Héry, Autier & Sankarananarayanan, 2010).  There is no questioning 
the usefulness of breast cancer incidence statistics for the general population.  However, 
data on subpopulations is also relevant as it can be used to identify possible disparities 
that may exist between certain subpopulations.  Interventions targeting the specific needs 
of the population at higher risk for breast cancer can then be developed to help decrease 
the level of disparity. 
2.1.2 Incidence of breast cancer in subpopulations  
The following describes studies that report on breast cancer in various populations 
to identify if any disparities exist.  
The study by Marrett & Chaudry (2003) reported the incidence of breast cancer in 
Ontario First Nations (FN) people in comparison with the Ontario population.  This 
retrospective cohort was comprised of 141 290 FN people from 1968 – 1991.  They were 
identified through files maintained by the federal government Department of Indian and 
Northern Affairs Canada that identifies those registered under the Indian Act.  This file 
was linked with the Ontario Cancer Registry (OCR) and vital statistics files to identify 
deaths and cancer diagnoses.  The incidence of breast cancer in Status Indian women was 
between 40 and 50% lower than the incidence in the general population (Marrett & 
Chaudry, 2003).  Marrett & Chaurdry (2003) hypothesized that since FN women 




may be protective resulting in a reduced incidence of breast cancer.  This study’s use of 
the OCR was a strength, as the OCR includes all residents of Ontario with cancer and is 
recognized for its high completeness of registration. A limitation of this study is that to be 
included in the FN cohort you had to be registered as a status Indian under the Indian Act.  
A proportion of FN people who were not status Indians were therefore not captured in the 
study.   
The impact of breast cancer may propagate differently across various populations.  
The study by Ali, Barnes, Kan & Beral (2010) compared incidence between British 
Indians and British whites in Leicester.  Leicester was chosen for analysis because it has 
a large population of British Indians.  Cancer data was acquired from the Trent Cancer 
Registry from January 2001 – December 2006 for residents of Leicester.  The Hospital 
Episode Statistics (HES) database records self-assigned ethnicity:  this database was 
linked with the cancer registry to identify the study cohort.  Cases of breast cancer 
(n=6615) were diagnosed during the study period and ethnicity data were available for 
98% of those cases.  Incidence rate ratios for breast cancer in British Indians were 
significantly less when compared to British Whites (Ali et al, 2010).  The strength of this 
study is the accuracy of the HES database that provided ethnic status for 98% of cancers.  
The cohort was however only from a particular region of the country, thereby possibly 
limiting the generalizability of the findings to the rest of England or the UK.   
 Sexual minorities exhibit known risk factors attributed to lung, colorectal and 
female breast cancer.  Sexual minorities included people that identify as lesbian, gay or 
bisexual.  The associated risk factors include smoking, alcohol use, obesity and 




between colorectal, lung and breast cancer incidence and sexual minority identity in 
California.  Data for this research was acquired from the California Health Interview 
Survey (CHIS), which includes data on sexual orientation.  To increase the sample of 
people identified as a sexual minority, 4 years of survey data were combined (2001, 
2003, 2005 and 2007).  Data on the incidence of cancer from 2001 - 2008 was taken from 
the California Cancer Registry.  The results reported two associations: being a lesbian 
was associated with a higher incidence of breast cancer and being a bisexual woman was 
associated with a lower incidence of breast cancer (Boehmer et al., 2014).  A strength of 
this study is that the survey is considered an accurate representation of California’s 
population; the results may however not be generalizable to the entire U.S. population.  
 Breast cancer incidence in some subpopulations in North America and Britain 
have been studied to better understand the burden of breast cancer. The population-based 
approach in these studies demonstrated how data from administrative databases can be 
used to identify subpopulations and then linked to cancer registries making it possible to 
calculate incidence in these groups.  A limitation of reporting on subpopulations with 
administrative data is the potential for misclassification error, where all of those within a 
subpopulation are not properly identified and included within the study.  This thesis used 
a similar approach to study breast cancer in people with ID. 
2.1.3 Incidence of breast cancer in people with intellectual disabilities 
Very few studies have been conducted that report on the incidence of cancer in 





In Finland, Patja, Eero & Iivanainen (2001) obtained participants though the use 
of a large countrywide survey.  The survey was able to capture people within the general 
population that had ID.  People suspected or known to have ID were further identified by 
examinations through the National Board of Health to assess if they met the criteria for 
ID.  Once identified the cohort was linked to the Finnish Cancer Registry to identify 
cancer diagnoses.  This study was a nationally representative cohort that had an average 
of 29-year follow-up with a total of 2173 individuals with ID.  The study expected 25.8 
cases of breast cancer and observed 23.  The incidence of breast cancer in both people 
with and without ID was comparable even though there was a low prevalence of smoking 
and lower participation in breast screening in people with ID (Patja et al., 2001).  This 
study’s strengths reside from a nationally representative cohort and a lengthy follow up 
period.  Biases were reduced because the cancer registration system in Finland is 
essentially complete.  A limitation of the study is the relatively small sample size, which 
limits the power of the study to make statistically significant observations.  Nonetheless, 
the study was useful because of the cohort methodology employed and the usage of 
administrative databases to identify cancer diagnoses.  The data compiled from the study 
was of importance as it demonstrated that breast cancer is comparable in the general 
population and the population with ID.  
The study by Sullivan et al., 2003 looked at breast cancer in people with ID 
coupled with breast screening practices.  Participants were identified through the 
Disability Services Commission of Western Australia.  Participants diagnosed with breast 
cancer were identified through the Western Australia Cancer Registry.  The study period 




of breast cancer among women with intellectual disability was 64.0 per 100 000 person-
years, in comparison with 146.7 per 100 000 person-years in the general population” 
(Sullivan et al., 2003, p.507).  Of the 2 370 women with ID included in the study sample, 
20 were diagnosed with breast cancer and 11 were <50 years of age at diagnosis.  The 
mean age at diagnosis was 49 years old.  A limitation of the study is the small proportion 
of people with ID that received a breast cancer diagnosis; this was in party due to 795 
cases being excluded due to incomplete information.  
A study by Janicki et al. (1999) looked at mortality in people with intellectual 
disabilities in New York State.  The population was identified through the state agency 
responsible for reviewing deaths involving children and adults with disabilities.  The 
deaths within this database included ICD codes, which were used to identify deceased 
people with ID.  The most prevalent causes of death in the study were cardiovascular 
disease, respiratory diseases and cancers.  Although, the older generations of people with 
ID still generally die at an earlier age, many are living as long as people without ID 
(Janicki et al., 1999).  This study is very important because its results suggest a trend that 
people with ID are living longer.  As their life expectancy increases their chances of 
living into the highest risk age groups for breast or other cancers also increases.   A 
limitation of the study is that only deaths in people associated with New York state’s ID 
agency were included.  Therefore, the study may not be representative of everyone with 
an ID.  As well, the study did not differentiate the types of cancer that were diagnosed in 
people with ID.   
 As the focus on the health needs of people with ID is increasing, more research 




their life expectancy increases, they are surviving into the age groups that are more often 
diagnosed with breast and other cancers.  The study conducted by Patja et al. (2001) 
concluded that the incidence of breast cancer in people with ID is comparable to that of 
the general population; this is inconsistent with findings from the study by Sullivan et al. 
(2003) that found breast cancer incidence in people with ID was lower than the general 
population.  Rigorous population level research is needed to accurately determine the 
incidence of breast cancer and identify its impact in people with ID.  More studies on this 
topic will make breast cancer incidence results more conclusive. 
2.1.4 Breast cancer stage at diagnosis in the general population 
Breast cancer stage is based on three characteristics:  tumour size and degree of 
spread, lymph node involvement, and degree of metastasis (Canadian Cancer Society, 
n.d.).  Staging is considered an important determinant of cancer outcome.  Information 
about breast cancer staging provides important information for clinical decision making 
but can also be used to determine the severity or impact of cancer in a population.   
Anderson, Reiner, Matsuno & Pfeiffer (2007) conducted a study that reported on 
shifting breast cancer trends in the United States.  To provide a broader context for breast 
cancer incidence, rates and age distributions were examined during five decades.  
Incidence data was obtained from the National Cancer Institute’s Connecticut Historical 
Database (CHD) from 1950-1972 and from the Surveillance, Epidemiology and End 
Results (SEER) program from 1973-2003.  The overall median age at diagnosis was 61.  
The mean age at diagnosis for women diagnosed at an early stage was 44, while the mean 
age for women diagnosed at a late stage was 73.  Incidence rates for early-stage tumours 




tumours decreased 2.9% (Anderson et al., 2007).  The strength of this study was in its 
large-scale population based design.  The SEER registry used to report incidence covers 
14% of the US population which, although is a small proportion of the total population, 
has meticulous and consistent data collection standards.  This study is useful because it 
provides valuable population based data about mean ages at diagnosis especially for those 
diagnosed at earlier ages.  This provides perspective on the age groups that should be 
included within my thesis.  
Henley, King, German, Richardson & Plescia (2010) performed a study to report 
on incidence rates for late-stage cancers of the colon, breast and cervix.  Data was 
retrieved from the Centre for Disease Control’s National Program of Cancer Registries 
and the SEER database.  In breast cancer patients Henley et al. (2010) reported that 
incidence rates for late stage breast cancer cases were lowest among women aged 50 – 
59, highest among women aged 60 – 69 and 70-79 years of age and highest among black 
women.  “During 2004-2006, approximately one third of breast cancers in the United 
States were diagnosed at a regional or distant stage, when treatment is not effective and 
survival is worse compared with cancers diagnosed at a localized stage” (Henley et al., 
2010, p. 6).  A regional stage refers to when the cancer has spread past the primary site to 
nearby lymph nodes or tissues and organs.  When cancer is limited to the organ of origin 
it is at a local stage.  Since this study specifically looked at late-stage cancer cases, it 
measured the proportion of cancers not detected at an earlier more treatable stage of 
disease.  A higher proportion of cancers diagnosed at later stages may be indicative of 
contributing factors such as low screening rates.   Although this study included 96% of 




Wisconsin.    This study was a very useful resource because it described the ages in 
which late stage breast cancer was the most prevalent.  This provides pertinent 
information about the age-range that should be included in my thesis.  This study also 
informs my research because of the retrospective cohort methodology that used linkages 
within administrative databases to highlight individuals diagnosed with cancer. 
A retrospective cohort conducted by McPhail, Johnson, Greenberg, Peake & Rous 
(2015) reported on the stage at diagnosis of breast, colorectal, lung, prostate and ovarian 
cancer and early mortality in England.  Data was retrieved from the National Cancer 
Registration Service’s (NCRS).  The Office of National Statistics provided information 
on deaths in England.  The study consisted of 152 821 people newly diagnosed with 
cancer, of which 42 071 were breast cancer.  The median age at diagnosis for breast 
cancer was 63.  McPhail et al. (2015) reported that greater than two-thirds of breast 
cancer subjects presented at either stage I or II.  The highest proportion of stage I breast 
cancers was diagnosed between the ages of 60 and 69.  A strength of this study was the 
completeness of the administrative databases, which cover between 80-90%, of the entire 
population of England.  A limitation of this study is that the data is limited to only 2012 
and therefore cannot demonstrate any trends.    
These studies provided important information on the most common ages that 
breast cancer is being diagnosed in the general population.  The studies by McPhail et al. 
(2015) and Anderson et al. (2007) reported comparable median ages at diagnosis of 63 
and 61 respectively.  The study by Henley et al. (2010) reported that the highest 




informed my research as they have demonstrated the importance of including people 
between the ages of 60 – 69 in my study population.   
2.1.5 Breast cancer stage at diagnosis in subpopulations 
It is useful to understand the descriptive epidemiology of breast cancer in various 
subpopulations.  As certain populations may be diagnosed at younger ages and at later 
stages in disease progression.   
The study conducted by Newman & Alfonso (1997) compared the age related 
differences in breast cancer stage at diagnosis between black and white patients in an 
urban community hospital.  The study reported on women diagnosed with breast cancer 
that were treated at the Long Island College Hospital between January 1990 and 
September 1994.  A retrospective review of hospital and physician records coupled with 
pathology reports and tumour registry data were used to determine the age, ethnic 
background and staging information of each study participant.  Newman & Alfonso 
(1997) found a significant shift towards a younger age at diagnosis among black females.  
The mean age for black patients was 56 in comparison to 63 for white patients.  Black 
patients were diagnosed at a younger age and at a more advanced stage at diagnosis.  
Newman & Alfonso (1997) proposed several explanations for the higher mortality and 
later stage at diagnosis among black breast cancer patients.  They hypothesized 
socioeconomic factors may result in poor access to medical care, a delay in seeking 
treatment and higher rates of obesity may contribute to breast cancer stage at diagnosis 
and mortality.  The biggest limitation of this study is the small sample size, making it 
difficult to establish statistical significance.  Another limitation is that, since the study 




This study informed my research project because it demonstrated that vulnerable 
populations may be diagnosed at different stages of disease progression. 
Deshpande, Jeffe, Gnerlich, Iqbal, Thummalakunta & Margenthaler (2009) 
conducted a retrospective population based cohort study that reported on the survival of 
Black and White women diagnosed with breast cancer.  The study period was from 
January, 1988 – December, 2003.  The database used to identify the study cohort was 
retrieved from nine registries in the SEER.  The final sample consisted of 224 930 Black 
and White women diagnosed with breast cancer.  Black women were more likely to be 
diagnosed with breast cancer in the <40 grouping as well as the 40-49 age groups while 
white women were more likely to be diagnosed in the >65 age group (Deshpande et al., 
2009).  Within each age grouping, black women were more likely to be diagnosed at a 
more advanced stage, have larger higher-grade tumours and lymph node involvement.  A 
greater proportion of black women died due to breast cancer when compared to White 
women.  The authors hypothesized that underutilization of mammographic screening may 
be responsible for the lower survival rates and later stages at diagnosis.   
Detroit has a large population of Arab-American women.  This large community 
provided authors Hensley, Alford, Soliman, Johnson, Gruber & Merajver (2009) with the 
opportunity to use administrative data to report on breast cancer in Arab women versus 
other ethnic groups.  Cancer information was provided by Detroit’s national tumour 
registry.  Women of Arab descent were identified in the registry through a validated 
name algorithm.  Breast cancer in Arab women was compared to white, non-Hispanic 
and African-American women.  Data were used from the inception of the Detroit SEER 




1973 and 2003.  The mean age at diagnosis was 60.  The majority of breast cancer cases 
were at a local stage.  Arab-American and African-American women were more likely to 
be diagnosed with regional disease (Hensley Alford et al., 2009).  In comparison with 
both European and African-Americans, Arab-American women were diagnosed at a 
younger age and regional stages of cancer (Hensley Alford et al., 2009).   
The aim of the study by Ginsburg et al., 2015 was to compare breast cancer stage 
at diagnosis in Chinese and South Asian women with the general population.  Women 
diagnosed with breast cancer between 2005 – 2010 were identified through Ontario 
population-based administrative databases. The databases used in this study included the 
Ontario Cancer Registry (OCR), the Ontario Health Insurance Plan (OHIP), the Canadian 
Institute for Health Information Hospital Discharge Abstract Database (CIHI-DAD), and 
the National Ambulatory Care Reporting System (NACRS).  The databases were linked 
through encoded identifiers.  The study design was a retrospective population-level cross 
sectional study of women that compared stage at diagnosis in three mutually exclusive 
groups:  Chinese women, South Asian women and the general population.  To determine 
ethnicity two validated surname lists were used.   The cohort consisted of 45 075 women, 
1543 of which were Chinese and 798 that were South Asian.  Chinese and South Asian 
women were more likely to be diagnosed before the age of 50 (Ginsburg et al., 2015).  
The results demonstrated South Asian women were more likely to be diagnosed at a later 
stage while Chinese women were less likely to be diagnosed at a later stage (Ginsburg et 
al., 2015).  Ginsburg et al. (2015) hypothesized South Asian women may not be exposed 
to breast education and prevention.  As well cultural values and stigma associated with 




screening programs.  In some Chinese communities in Ontario, community agencies have 
collaborated with cancer agencies on health promotion initiatives that encourage healthy 
lifestyles and cancer screening.  A limitation of this study is the surname algorithm used 
to identify Chinese and South Asian last names, which likely excluded many women 
particularly of South Asian descent.  
Lipscombe et al. (2015) examined the stage at cancer diagnosis in women with 
diabetes.  New research is suggesting that female patients with diabetes may be at a 
higher risk of developing breast cancer.  They may also be at a higher risk of more 
advanced breast cancers at diagnosis.  The study objective was to compare women with 
and without diabetes according to their stage at diagnosis.  This Ontario population based 
study used the OCR, Cancer Care Ontario (CCO) stage data, the Ontario Diabetes 
Database (ODD), the CCO Ontario Breast Screening Program (OBSP), OHIP, CIHI-
DAD and the Registered Persons database (RPDB).  Information from these databases 
was linked using encoded identifiers.  This study employed a cross-sectional study design 
to compare the stages at diagnosis between women with and without diabetes.  The study 
population consisted of Ontario women between the ages of 20 – 105, that were newly 
diagnosed with breast cancer between January 1, 2007 and December 31, 2012. Cancer 
stages were categorized I – IV.  The results demonstrated that the majority of women 
presented with stage I or II breast cancer.  Women diagnosed with diabetes were 
significantly more likely to be diagnosed at a more advanced stage of breast cancer than 
those without.  Women with diabetes were more likely to have larger tumours and lymph 
node metastases at diagnosis.  Diabetes may be a risk factor that predisposes women to 




women with a longer duration of diabetes.  The strength of this study is the population-
based data that used validated methods to identify both diabetes and breast cancer..  
The studies by Newman & Alfonso (1997), Deshpande et al. (2009) and Hensley 
Alford et al. (2009) demonstrated that being in a visible minority was correlated with 
being diagnosed at a younger age and a later stage.  Some hypothesized factors for this 
observation are attributed to socioeconomic factors.   
Both studies by Ginsburg et al. (2015) and Lipscombe et al. (2015) implemented 
cross-sectional methodologies to report the stage of breast cancer in Ontario’s population.  
I intend to implement a similar study design in a defined population to report on the stage 
of breast cancer.  These studies demonstrated how Ontario’s administrative databases can 
be used to identify both the study population and breast cancer diagnoses.  
2.1.6 Cancer stage at diagnosis in people with intellectual disabilities 
Tuffrey-Wijne, Bernal, Hubert, Butler & Hollins (2009) performed an 
ethnographic study that aimed to provide insight into the experiences of people with ID 
with cancer.  Of the 13 participants, 10 were diagnosed at advanced stages in disease 
progression.  The mean age at diagnosis for the study participants was 53.  Cancer 
diagnoses were often dependent on someone other than the patient either noticing 
something was wrong or interpreting complaints or behavioural changes.  Four patients 
complained of symptoms but their concerns were either ignored or disbelieved.  
Misdiagnosis from a physician was a contributing factor to delays in the appropriate 
diagnoses.  This study provides rich insights into the lives and experiences of people with 




A study performed by Satgé et al. (2014) reported on the age and stage at 
diagnosis of 11 women with ID diagnosed with breasts cancer.  The study sample was 
retrospectively selected from a single hospital amongst all women treated for invasive 
breast cancer from 1989 - 2006.  The study reported on the tumour grade, age, tumour 
size and disease stage at diagnosis in 11 patients with ID compared to patients without 
ID.  The mean age at diagnosis for women with ID was 55.64 in comparison with 62.35 
in those treated without ID.  Women with ID were at a higher risk of having greater 
tumour size, metastases to lymph nodes and higher tumour grades. Unadjusted OR’s 
showed women with ID were 3.2 times more likely to be diagnosed at stage II and 10.2 
times more likely to be diagnosed at stage III when compared to women without ID.  
Although women with ID were more likely to be diagnosed at a later stage, significant 
differences were not observed in the histological types of breast cancer in both groups of 
women.  Due to this finding Satgé et al. (2014) hypothesized breast cancers in women 
with ID were not more aggressive, but rather delays in diagnosis were responsible for the 
later stage at diagnosis.   Limitations of this this study are that it was not population based 
and few patients were studied.  Nonetheless, this was the first study of breast cancer 
characteristics at diagnoses in women with ID. 
2.1.7 Health disparities experienced by people with intellectual disabilities 
It has been well established that social and environmental factors play an 
important role in determining the health of the general population (Beiser & Stewart, 
2005).  More recently, the disparities in the health status of people with ID have been 
attributed to social and environmental factors (Hatton & Emerson, 2015).   Researchers 




environments, yet little is known about how their socioeconomic position affects their 
overall health  (Graham, 2005). 
The social and environmental factors experienced by people with ID places them 
at a higher risk of experiencing poor health.  People with ID are often unemployed, have 
lower levels of literacy and live in unsafe, lower income neighbourhoods, which are all 
associated with poor health (Ouellette-Kuntz et al., 2005).   
This population also experiences the negative effects of stigma.  The extent to 
which negative societal values are embedded in social institutions perpetuates and 
restricts access for people with ID to opportunities that improve health (Llewellyn, 
Vaughan & Emerson, 2015).  The stigma experienced by people with ID creates 
additional distress and erects barriers that can lead to inadequate health care.  People in 
society, including healthcare providers, who hold negative views of people with ID are 
more likely to bully, avoid, ridicule, infantilize or harass them (Llewellyn et al., 2015).  
The cultural, societal and environmental barriers coupled with the discrimination 
experienced by people with ID act as barriers to positive health and life experiences 
(Emerson & Baines, 2010). 
Some researchers have suggested that people with ID experience a double 
disadvantage: they not only have to cope with their disability itself but also with the 
added burden of compromised health and inadequate health services (Ali et al., 2013; 
Beiser & Stewart, 2005).  For example difficulties in communication experienced 
between people with ID and their health care providers can create a major challenge in 
addressing their complex health needs (Ouellette-Kuntz, 2005).  Communication 




health problems, makes people with ID more likely to receive suboptimal medical care 
(Ali et al., 2013; Emerson & Baines, 2011; Hollins, Attard, von Fraunhofer, McGuigan & 
Sedgwick, 1998; Ouellette-Kuntz, 2005; Perkins & Moran, 2010).   
The current structure of the healthcare environment does not effectively support 
people with ID.  Currently chronic disease management frameworks rely heavily on self-
management.   While these self-management methods have proven to be successful in 
improving health status and reducing hospitalizations in people without ID (Coleman, 
Austin, Brach & Wagner, 2009; Lawn & Schoo, 2009), people with ID may not be 
capable of self-management.  It is important that healthcare providers alter disease 
management models to fit the needs of people with ID to optimize their health.  People 
with ID need to be actively engaged and involved with their health at their level of 
understanding through tailored health awareness, self-advocacy, health literacy, health 
promotion and caregiver education (Ervin, Hennen, Merrick & Morad, 2014).    
Evidence has demonstrated that people with ID are more likely to experience a 
variety of health disparities when compared to people without ID.  In this research, 
disparities refer to “differences in health without inference to the cause of these 
differences” (Krahn, Hammond & Turner, 2006).  The differences in health that were 
addressed are differences in the incidence of breast cancer and stage at breast cancer 
diagnosis using population level data.    
2.1.8 Summary 
There is little research in the areas of incidence and stage at diagnosis for people with ID 
diagnosed with breast cancer.  This information is pertinent to assess the impact breast 




information on stage at diagnosis that may highlight disparities within the healthcare 




















3 MANUSCRIPT 1 































Background:  People with intellectual disabilities represent approximately 1% of 
Ontario’s population and they experience a variety of disadvantages.  As the life 
expectancy of people with intellectual disabilities increases they are more likely to 
experience the same age-related health concerns as people without intellectual 
disabilities, such as cancers.  Very little cancer research has been performed in this 
population, and even less breast cancer specific research.   
Objective:  The objective is to describe and compare breast cancer incidence in women 
with and without intellectual disabilities living in Ontario. 
Methods:  Ontario based population-level administrative databases were used to identify 
women with and without ID between the ages of 30 to 105 diagnosed with breast cancer.  
To determine the yearly cumulative breast cancer incidence from 2000-2014, the total 
number of women (n=119,516) were linked to the Ontario Cancer Registry identifying 
new breast cancer diagnoses.    
Results:  We identified 330 women with intellectual disabilities and 119 186 women 
without intellectual disabilities diagnosed with breast cancer throughout the study period.  
Baseline characteristics of women with intellectual disabilities identified there were more 
likely to reside in the lowest income quintiles.  The age composition of women with 
intellectual disabilities was younger than women without.  Their mean age at diagnosis 
was 57 in contrast with 62 in women without intellectual disabilities.  The incidence of 
breast cancer in women with intellectual disabilities was not significantly different from 




Conclusions:  The yearly breast cancer incidence was comparable between both cohorts 
of women, suggesting women with intellectual disabilities are at no greater or lesser risk 





















3.2.1 Intellectual disability 
Currently in Canada, people with intellectual disabilities (ID) make up 
approximately 0.78% of the total population (Lunsky et al., 2013).   ID is defined by the 
Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 as impairments in 
adaptive functioning and general mental abilities (American Psychiatric Association, 
2013).  Adaptive functioning is evaluated in three domains: conceptual, social, and 
practical (American Psychiatric Association, 2013).  Conceptual functioning refers to 
skills in language, literacy, and math.  The social domain refers to an individual’s social 
skills such as empathy, interpersonal communication, and social problem solving.  Lastly, 
the practical domain refers to areas based on the activities of daily life.  Intelligence 
quotient (IQ) tests are used to assess intellectual functioning gauging an individual’s 
general mental abilities.  An IQ of 70 or less is indicative of a limitation in intellectual 
functioning (American Psychiatric Association, 2013).  Symptoms of ID must begin in 
the developmental period of life, and ID can be caused by genetic, congenital or acquired 
factors.  Some examples of conditions that are commonly associated with ID are Down 
syndrome, fragile X syndrome, and fetal alcohol syndrome (Tasman et al., 2015). 
 As the life expectancy of people with ID increases, they become more likely to 
experience age-related health concerns or diseases consistent with those found in people 
without ID (Bittles et al., 2002; Kapell et al., 1998; Perkins & Moran, 2010).  Some of 
the age-related health concerns or diseases include cardiovascular pathology, respiratory 




 Cancer, and breast cancer in particular, is a significant contributor to the 
morbidity and mortality of women in the general population.  Nonetheless, breast cancer 
has not been well studied in people with ID to assess its impact in this vulnerable 
population.  For instance, very little research has been conducted that compares breast 
cancer incidence in women with and without ID.  The lack of research in this field may 
be attributed to the fact that historically people with ID had a significantly lower life 
expectancy (Sullivan et al., 2003).   
3.2.2 Breast cancer incidence 
 Breast cancer is a malignant disease that develops in breast tissue.  One in nine 
Canadian females are expected to be diagnosed with breast cancer in their lifetime 
(Canadian Cancer Statistics, 2016).  The majority of women diagnosed with breast cancer 
are between the ages of 50 and 74 (Cancer Care Ontario, 2015a).  As the Canadian 
population ages, the number of people diagnosed with age related diseases such as breast 
cancer is also expected to increase. 
Few studies have been conducted on the incidence of cancers in people with ID 
and even fewer have been conducted looking specifically at breast cancer using 
administrative health data.  A study by Sullivan et al. (2003) examined breast cancer in 
people with ID coupled with breast screening practices.  Participants were identified 
through the Disability Services Commission of Western Australia.  Those with breast 
cancer were identified through the Western Australia Cancer Registry.  This study used 
administrative databases to identify the study participants.  Once the participants were 
identified, the study population was linked to the cancer registry to identify breast cancer 




the age of 25.  2 370 women with ID were included in the study, 20 of those women were 
diagnosed with breast cancer with a mean age at diagnosis of 49 years of age.  “The 
standardized breast cancer incidence rates (SIR) for women with ID across all age groups 
was lower than what would be expected in women without ID” (Sullivan et al, 2003, 
p.509).  The data demonstrated that the SIRs were significantly lower from 1982-1995, 
but were not significantly lower from 1995 – 2000 (Sullivan et al., 2003).  The reduced 
rate of overall breast cancer specifically before 1995 may be partially due to the lower 
life expectancy of people with ID (Sullivan et al., 2003).  As the life expectancy of 
people with ID continues to increase, current research on breast cancer incidence in 
people with ID may yield different results.  A limitation of this study, however, is the 
small proportion of people with ID that received a breast cancer diagnosis.  This study 
needs to be developed further to address these limitations and provide updated results on 
breast cancer in people with ID.  This study is particularly important, as it is was the only 
study that used administrative databases to report population level data specifically on 
breast cancer incidence. 
3.2.3 Significance and objectives 
Currently no studies have been performed in Canada that report on the incidence 
of breast cancer in people with ID.  Previous research outside of Canada has focused 
broadly on cancer in general, but little breast cancer specific research has been conducted 
(Patja et al., 2001; Sullivan et al., 2003). 
Although still shorter than people without ID, the life expectancy of people with 
ID is increasing in a parallel fashion to people without ID (Ouellette-Kuntz et al., 2005).  




women with and without ID.  It is often wrongly assumed by health care practitioners that 
women with ID are not at the same risk for developing breast cancer as women without 
ID (Ouellette-Kuntz et al., 2005).  
Although there are some population-based studies that reported on the incidence 
of breast cancer in people with ID none have been conducted since 2003 and none have 
been done in Canada.  This research aims to provide current population level data to 
demonstrate breast cancer incidence in both women with and without ID.   Although this 
research is not able to identify causation, it can identify whether a disparity exists 
between both groups of women.    
 The objectives of this research are to:  1) Describe the incidence of breast cancer 
between women with and without intellectual disabilities and 2) Compare the incidence 















3.3.1 Study design 
This research used retrospective population cohorts to report on yearly breast 
cancer incidence from 2000 – 2014 in women with and without ID.  This study design 
allowed the researcher to go back in time to identify women with and without ID and 
follow them throughout the study period to identify whether they were diagnosed with 
breast cancer.  Women with and without ID retrieved from administrative databases were 
included in this study.  This study was approved by the institutional review board at 
Sunnybrook Health Sciences Centre, Toronto, Canada and the University of Ontario 
Institute of Technology.    
3.3.2 Data sources and linkages 
Administrative health databases collect, store and de-identify health data that is 
compiled through health care programs (Manitoba Centre for Health Policy, 2013).  The 
data is initially collected for administrative or billing purposes but can be a rich source of 
information to answer health and health services related research questions.  
Administrative health databases provide researchers with historical data allowing them to 
study changes over time.  
The Institute of Clinical Evaluative Science (ICES) has access to a vast range of 
secure administrative health data in Ontario and is known internationally as a credible 
source of high quality health research (ICES, 2016).  Data collected by ICES has personal 
identifiers removed, which are replaced with a unique confidential ICES key number 




Plan (OHIP) has an associated IKN consistent through all health service databases within 
ICES’s inventory of administrative databases (ICES, 2016).  These datasets were linked 
using unique encoded identifiers and analyzed at ICES.  The IKN is an essential 
component to the research conducted at ICES since it is used to successfully link 
individuals across databases.     
3.3.3 Databases 
Data for this study was acquired from ICES.  Eight administrative databases were 
used including six health databases, one registry and census data.   The health databases 
were the Ontario Mental Health Reporting System (OMHRS), the Canadian Institute of 
Health Information Discharge Abstract Database (CIHI-DAD), the National Ambulatory 
Care Reporting System (NACRS), Same Day Surgery (SDS), the Ontario Health 
Insurance Plan (OHIP), and the Ontario Cancer Registry (OCR).  The administrative 
health databases include clinical information about Ontario residents.  Some of the 
information included in the databases are:  mental health problems, inpatient hospital 
discharges, emergency department visits, same day surgeries, physician claims and 
cancer diagnoses (See Appendix B, Table 1).  
 The registry accessed for this study was the Registered Persons database 
(RPDB), which includes demographic information on all Ontario residents eligible for 
OHIP.  The Canadian census was accessed for postal codes and information on 




3.3.4 Study populations 
Two cohorts of Ontario women 30 to 105 years of age were created from the 
databases.  One consisted of women with ID, and the other a comparison cohort of 
women without ID.   
Diagnostic codes from five administrative health databases held at ICES (See 
Appendix B, Table 2) were used to identify people with ID (See Appendix B, Table 3).   
A coding algorithm to identify people with ID developed by the Health Care 
Access Research and Developmental Disabilities research program (H-CARDD) was 
used in this project (Lunsky et al., 2013).  ID is often only recorded in health records 
when an individual is first assessed during childhood.  To ensure people with ID were not 
excluded from the sample, they were identified from the inception of the five 
administrative health databases (Lin et al., 2013).  Using the widest time frame possible 
is a strategy that has been evaluated by Lin et al. (2013) to maximize the detection of ID 
cases and aids in identifying people with ID across all ages. 
The Ontario female population without ID was identified using the RPDB to serve 
as a comparator. 
Women with and without ID diagnosed with breast cancer were identified in the 
OCR and linked using the IKN.  The OCR includes information about all newly 
diagnosed cases of breast cancer in Ontario.   
Exclusion criteria  
Individuals under the age of 30 and over the age of 105 in both the comparison 
cohort and the cohort of people with ID were excluded from this study.  People under 30 




that were not eligible for OHIP coverage at any point in the yearly observation window.  
Prevalent cases of breast cancer were excluded. 
3.3.5 Other variables and measures 
Baseline demographic characteristics such as age and income quintile were 
reported.  Age was determined using the RPDB.  Retrieved from the RPDB, forward 
sortation area (FSA) data based on the first three characters of the postal code (Statistic 
Canada, 2008) were used to determine the neighbourhood income level for individuals 
from the Canadian census.  Income quintiles highlight information about a person’s 
socioeconomic status.  The covariates (age and income quintile) were used to describe 
both cohorts of women. 
3.3.6 Data analysis 
3.3.6.1 Breast cancer incidence  
Cumulative incidence was calculated yearly from 2000 - 2014 in both cohorts. 






The denominator was the number of women in a given year in Ontario between 30 and 
105 with ID that were eligible for OHIP, with no prior breast cancer diagnosis. 
  
 
Number of women between 30 and 105 with a 
new diagnosis of breast cancer in Ontario with ID 
in (year) 
Number of women between 30 and 105 no history 
of breast cancer in Ontario with ID in (year) 
Women with ID yearly  











The denominator was the number of women in a given year in Ontario between 30 and 
105 without ID that were eligible for OHIP, with no prior breast cancer diagnosis.   
3.3.6.2 Incidence rate ratio 
To address objective 2, yearly incidence rate ratios were calculated to compare 
breast cancer incidence between women with and without ID.  The incidence in women 
with ID was divided by the incidence in women without ID.  The formula used to 





3.3.6.3 Age-Specific Incidence 
Cumulative age-specific incidence was calculated from 2010 – 2014 to compare 
breast cancer incidence by age between both cohorts of women. 
 
 
Number of women between 30 and 105 without an 
ID with a new diagnosis of breast cancer in 
Ontario (year) 
Number of women between 30 and 105 without 
ID with no history of breast cancer in Ontario in 
(year) 
Women without ID yearly 
breast cancer incidence   = 
 
Breast cancer incidence in women with ID in 
Ontario (year) 
Breast cancer incidence in women without ID in 
Ontario (year) 
Yearly Breast Cancer 
Incidence Rate Ratio = 
 
Number of women with ID and a new diagnosis 
of breast cancer in Ontario (in the specified age 
range) 
Number of women with ID with no history of 
breast cancer in Ontario  
 (in the specified age range) 
Age-Specific Incidence in 
women with ID 





3.3.6.4 Standardized incidence and incidence rate ratio 
Age standardized incidence rates (ASIR) and standardized rate ratios for breast 
cancer were calculated using the 2006 Canadian population as a standard to account for 
different age distributions.  Age adjustments make both cohorts more comparable by 
adjusting for differences in population structures. 
3.3.6.5 Significance Testing 
 P-values were used to report on the statistical significance of baseline 
demographic variables between women with and without ID.  Two-tailed Z-tests for 
sample proportions were used to determine p-values, where p < 0.05 was considered 
statistically significant.  Z-test for comparing mean age were used to determine a 
statistical significance at p < 0.05. 
Confidence intervals of 95% were used to describe the incidence and incidence 
rate ratios in women with and without ID.  They were used to provide a measure of the 
precision of the incidence point estimate where there was a 95% probability that the true 
value is within the interval (Baptist du Prel, Hommel, Rohrig & Blettner, 2009).  The size 
of the sample and variability of the data directly affect the size of the confidence interval 
(Baptist du Prel et al., 2009).  Larger sample sizes lead to narrower confidence intervals.  
A wide confidence interval is indicative of a small sample.  When there is high dispersion 
in the sample, the conclusions are less certain resulting in a wider confidence interval.  
Regardless of the size of the confidence interval, the point estimate based on the data in 
the sample provides the best approximation of the true value (Baptist du Prel et al., 2009). 
Confidence intervals were included to provide an approximation of statistical 




estimate of women without ID the results between both cohorts are not considered 























3.4.1 Baseline characteristics of women with and without ID in 2000 and 2014 
 Tables 1 and 2 show the baseline characteristics of Ontario females, by ID.  These 
characteristics include age and income quintile at the beginning (2000) and final year of 
the study period (2014).  Both years showed that the majority of women with and without 
ID were between the ages of 30-59.  Women with ID in both 2000 and 2014 were more 
likely to reside in the lowest income quintiles (quintile 1=27.9% (2000), 27.5% (2014), 
quintile 2= 21.8%(2000), 20.5% (2014)).  In contrast, women without ID were roughly 

































Baseline characteristics of women with and without intellectual disability by age group 








N = 4,501,177 
 
Age on Dec 31 (n, col %) 
30-39 years 
3,214 (31.4%)* 1,327,974 (29.6%) 
1,331,188 (30.0%) 
40-49 years 
3,006 (29.4%)* 1,142,803 (25.4%) 1,145,809 (25.5%) 
50-59 years 
1,850 (18.1%) 806,704 (18.0%) 808,554 (18.0%) 
60-69 years 
996 (9.7%)* 536,707 (12.0%) 537,703 (11.9%) 
70-79 years 
664 (6.5%)* 429,156 (9.6%) 429,820 (9.5%) 
80+ 
501 (4.9%)* 247,602 (5.5%) 248,103 (5.5%) 
Income quintile (n, col %) 
Quintile 1 – 
Low 
2,858 (27.9%)* 870,708 (19.4%) 873,566 (19.4%) 
Quintile 2 2,234 (21.8%)* 882,329 (19.6%) 884,563 (19.7%) 
Quintile 3 1,823 (17.8%)* 859,480 (19.1%) 861,303 (19.1%) 
Quintile 4 1,681 (16.4%)* 829,233 (18.5%) 830,914 (18.5%) 
Quintile 5 – 
High 
1,388 (13.6%)* 854,271 (19.0%) 855,659 (19.0%) 
Missing 247 (2.4%) 194,925 (4.3%) 195,172 (4.3%) 
* Compared with the comparison cohort of women without ID, statistically significant at p < 0.01, 





Baseline characteristics of women with and without intellectual disability by age group 




N= 17, 472 
No ID Cohort 
N= 5,548,903 
Total 
N=  5,566,375 
Age on Dec 31 (n, col %) 
30-39 years 4,238 (24.3%)* 1,164,744 (21.0%) 1,168,982 (21.0%) 
40-49 years 4,233 (24.2%)* 1,259,480 (22.7%) 1,263,713 (22.7%) 
50-59 years 4,409 (25.2%)* 1,256,815 (22.6%) 1,261,224 (22.7%) 
60-69 years 2,662 (15.2%)* 902,262 (16.3%) 904,924 (16.3%) 
70-79 years 1,167 (6.7%)* 532,514 (9.6%) 533,681 (9.6%) 
80+ 763 (4.4%)* 433,088 (7.8%) 433,851 (7.8%) 
Income quintile (n, col %) 
Quintile 1 – 
Low 
4,807 (27.5%)* 1,001,124 (18.0%) 1,005,931 (18.1%) 
Quintile 2 3,587 (20.5%)* 1,024,639 (18.5%) 1,028,226 (18.4%) 
Quintile 3 3,095 (17.7%)* 1,026,928 (18.5%) 1,030,023 (18.5%) 
Quintile 4 2,976 (17.0%)* 1,085,922 (19.6%) 1,088,898 (19.6%) 
Quintile 5 – 
High 
2,687 (15.4%)* 1,066,927 (19.2%) 1,069,614 (19.2%) 
Missing 320 (1.8%) 343,363 (6.2%) 343,683 (6.1%) 
* Compared with the comparison cohort of women without ID, statistically significant at p < 0.01, 




3.4.2 Incidence of breast cancer in women with and without ID  
From 2000 – 2014 
There were 119, 516 incident breast cancers identified between January 1, 2000 
and December 31, 2014.  Of these women, 330 had ID.  Table 3 shows the background 
characteristics of breast cancer patients including age and income quintile by ID status.  
A greater proportion of women with ID (29.3%) were diagnosed at a younger age (<50) 
in comparison with 21.3% of women without ID (p<0.01). The mean ages at diagnosis 
for women with and without ID was 57 and 62 respectively and the difference was 
statistically significant (p<0.05).  For women without ID in all age groups, the proportion 
of women diagnosed with breast cancer was greatest in the highest income quintiles.  The 
reverse was true in women with ID; where the highest proportion of women diagnosed 
with breast cancer resided in the lowest income quintile.  
Table 4 shows the crude and age-standardized breast cancer incidence with 95% 
confidence intervals (CI) as well as the crude and age-standardized incidence rate ratios 
with 95% CI’s.  For each year observed, the 95% CI’s for breast cancer incidence in 
women with ID were wide, and included the point estimate for women without ID 
(Figure 1), indicative of non-significant differences.  Figure 2 shows breast cancer 
incidence in both groups of women with trendlines for women with and without ID.  
When compared, the trendlines were not significantly different (p=0.5). 
Over the 15-year period, the standardized rate ratios comparing women with and 
without ID ranged between 0.59-1.38.  None of the years showed statistically significant 
rate ratios.  Thus, the incidence for breast cancer in both women with and without ID was 





Characteristics of women with breast cancer (N=119,516), by intellectual disability status (Ontario, 5-year periods) 
 
 
Year 2000 - 2004 Year 2005 - 2009 Year 2010 - 2014 Total 
 ID No ID ID No ID ID No ID ID No ID 
 
N=84 N=35740 N=100 N=39234 N=146 N=44212 N= 330 N = 119 186 
Average age at breast cancer diagnosis 
Mean 57.7 61.5 56.0 61.6 58.5 62.2 57.4a 61.7 
 
Age groups (n, col %) 
30-39 years 6 (7.1%) 1756 (4.9%) 8 (8.0%) 1711 (4.4%) 8 (5.5%) 1732 (3.9%) 22 (6.7%)* 5199 (4.4%) 
40-49 years 20 (23.8%) 6276 (17.6%) 23 (23.0%) 6931 (17.7%) 32 (21.9%)* 6922 (15.7%) 75 (22.7%)* 
20129 
(16.9%) 
50-59 years 19 (22.6%) 8814 (24.7%) 
35 
(35.0%)* 


























Income quintile (n, col %) 
Quintile 1 – 
Low 
26 (31.0%)* 6432 (18.0%) 
23 
(23.0%) 
6965 (17.8%) 38 (26.0%)* 7644 (17.3%) 87 (26.4%)* 
21041 
(17.7%) 
Quintile 2 19 (22.6%) 7069 (19.8%) 
19 
(19.0%) 
7560 (19.3%) 30 (20.6%) 8527 (19.3%) 68 (20.6%) 
23156 
(19.4%) 





7720 (19.7%) 33 (22.6%) 8664 (19.6%) 68 (20.6%) 
23470 
(19.7%) 
Quintile 4 15 (17.9%) 7111 (19.9%) 
22 
(22.0%) 
8262 (21.1%) 20 (13.7%)* 9341 (21.1%) 57 (17.3%) 
24714 
(20.7%) 
Quintile 5 - 
High 
8 (9.5%)* 7951 (22.3%) 
14 
(14.0%) 




* Compared with women without ID, statistically significant at p < 0.05, according to the two tailed Z test for comparing proportions 
a Statistically significant at p < 0.05, according to the Z test for comparing independent sample means 


















Crude and age-standardized breast cancer incidence (per 1000) among Ontario females with ID and without ID and breast 
cancer rate ratios (Ontario, from 2000-2014) 
 
Year Population Incidence 
Crude incidence per 1000 
persons 
Standardized incidence rate 
per 1000 persons 








a Rate per 1000 
persons 95% CI
a Rate 95% CI
a Rate 95% CI
a 
2000 





No ID 6846/3623352 1.89 1.84-1.93 2.04 2.00-2.09 
2001 





No ID 7031/3707948 1.90 1.85-1.94 2.04 1.99-2.09 
2002 





No ID 7332/3794095 1.93 1.89-1.98 2.08 2.03-2.12 
2003 





No ID 7119/3872047 1.84 1.80-1.88 1.96 1.91-2.00 
2004 





No ID 7412/3943686 1.88 1.84-1.92 1.98 1.94-2.03 
2005 





No ID 7590/4010489 1.89 1.85-1.94 1.98 1.93-2.02 
2006 





No ID 7676/4008820 1.91 1.87-1.96 1.98 1.93-2.02 








No ID 7922/4014271 1.97 1.93-2.02 2.02 1.98-2.07 0.83 – 
1.72 
2008 
ID 25/12771 1.96 1.27-2.89 2.16 1.37-3.25 
1.02 0.69-1.5 1.10 0.74-1.62 
No ID 7857/4081289 1.93 1.88-1.97 1.96 1.91-2.00 
2009 





No ID 8189/4152503 1.97 1.93-2.02 1.99 1.94-2.03 
2010 





No ID 8634/4221050 2.05 2.00-2.09 2.05 2.00-2.09 
2011 





No ID 8782/4296895 2.04 2.00-2.09 2.03 1.99-2.07 
2012 





No ID 8738/4366498 2.00 1.96-2.04 1.98 1.94-2.02 
2013 





No ID 8807/4428435 1.99 1.95-2.03 1.95 1.91-1.99 
2014 










Age-specific breast cancer incidence (per 1000) among Ontario females with ID and without ID (Ontario, from 2000-2014) 
 
Age Population Incidence Age-specific incidence per 1000 persons 
Rate per 1000 
persons 
95% CIa 
30-39 years ID 9/17997 0.50  0.23 - 0.95 
No ID 1907/4686278 0.41 0.39 - 0.43 
40 – 49 years ID 33/20423 1.62 1.11 - 2.27 
No ID 7362/5278722 1.39 1.36 - 1.43 
50 – 59 years ID 43/18162 2.37 1.71 - 3.19 
No ID 10706/4869064 2.2 2.16 - 2.24 
60 – 69 years ID 33/9661 3.42 2.35 - 4.80 
No ID 11403/3400808 3.35 3.29 - 3.42 
70+ years ID 28/6991 4.01 2.77 – 5.78  
No ID 12834/3556668 3.61 3.55 – 3.67 










Trend in breast cancer incidence rates, Ontario females with and without ID, 2000-2014 with 95% CI 
 

















































Trend in breast cancer incidence rates, Ontario females with and without ID, 2000-2014 with trendlines 
 
 
Standardized to the Canadian population, Census 2006 
 
y (ID)= 0.0175x + 1.8616

















3.5.1 Summary of findings 
 This is the largest population-based cohort study of ID and breast cancer ever 
conducted.  To date no study has reported on the incidence of breast cancer in Ontario 
women with ID.  The objective was to report on cumulative breast cancer incidence in 
women with and without ID in Ontario.  Baseline characteristics of women with ID 
identified they were more likely to reside in lower income neighbourhoods and were 
younger than women without ID.  During the study period, a total of 119 516 women 
diagnosed with breast cancer were identified.  Of those women, 330 had ID.  The 
incidence of breast cancer in women without ID remained fairly constant during the 15-
year study period, while the incidence in women with ID was more variable.  Nonetheless 
no significant differences were noted between both groups of women.   
3.5.2 Results in context of past research 
When examining the combined age distribution of women with and without ID in 
2000 and 2014, there is evidence of an aging population.  When comparing the age 
profiles in 2000 to those in 2014, there were fewer younger women (<50) and more older 
women (≥ 50) in 2014.  Like the general population of Canada, women with ID are 
experiencing a demographic shift to an aging population (Statistics Canada, 2016).  
Despite the pattern of aging over time, the age distribution of women with ID 
demonstrated that the proportion of women with ID who are young is greater than in 
women without ID.  This finding was consistent with research by Lunsky et al. (2013), 




found that the age composition of people with ID in Ontario tended to be younger when 
compared to people without ID. 
The income quintile distributions between women with and without ID were 
significantly different regardless of the years.  Women without ID were roughly evenly 
distributed throughout the five income quintiles. Women with ID were unevenly 
distributed across the income quintiles with the highest proportion of women residing in 
the lowest income quintile.  This is consistent with Ontario studies by Lunsky et al. 
(2013) and Lin et al. (2013), which found that greater than twice the number of adults 
with ID resided in the lowest than in the highest income quintiles.  This finding is also 
concordant with a British study by Emerson & Hatton (2008), which found the greatest 
proportion of people in their study with ID resided in the lowest income quintiles.  The 
consistency in the age and income quintile distribution between studies suggests that our 
sample is representative of women with ID.  
In this population study, the results showed that breast cancer incidence in women 
without ID over the 15-year period did not vary significantly year to year.  In women 
with ID, breast cancer incidence was more variable, likely due to the small sample size.  
The results demonstrated that breast cancer incidence in women with ID was not 
significantly different from women without ID.  This finding is in accordance with 
another population level study from Finland by Patja et al. (2001).  
The results of the present study were, however, conflicted with a retrospective 
community sample study from Australia by Sullivan et al. (2003), that found the overall 
incidence of breast cancer in women with ID from 1982 – 2000 was less than the general 




women (n=20) who were diagnosed with breast cancer in the study.  Sullivan et al.’s 
(2003) findings may also be due to the lower life expectancy of women with ID, 
especially in the earlier years of the study.  In fact, Sullivan found that in later years 
(1995 – 2000) breast cancer was not significantly different in both groups of women, 
concordant with the present study.   
The present study did not show women with ID at a greater or lesser risk of being 
diagnosed with breast cancer.  Even though breast cancer risk factors such as nulliparity 
are more likely in women with ID (Emerson & Baines, 2011), no excess breast cancer 
was demonstrated in this study. 
 A pattern was established in this study that demonstrated women with ID 
diagnosed with breast cancer tended to be younger than women without ID.  This pattern 
is further confirmed through the age-standardized rate ratios, which were almost always 
higher than the crude rate ratios indicating women with ID are younger than women 
without ID.  A significant difference (p<0.05) was identified in the average age at breast 
cancer diagnosis in women with and without ID, which were 57 and 61 respectively.  
This observation may be due to the fact that the age profile of women with ID was 
younger than that of women without ID.  Further calculations of age specific incidence 
demonstrated breast cancer was comparable in both cohorts throughout all age ranges 
(Table 5).  Nonetheless this finding is strikingly consistent with past research by Satgé et 
al. (2014), which found the mean age at diagnosis in women with ID to be 56 and 62 in 




3.5.3 Strengths and limitations 
 This study used population level data to identify women with and without ID 
diagnosed with breast cancer.  By using administrative health databases, it was possible 
to identify a relatively large number of women with ID and breast cancer despite women 
with ID representing only about 1% of the general population.  In addition, a high quality 
cancer registry was used making it unlikely that cases of breast cancer were missed.      
 This study was subject to some limitations inherent to the use of administrative 
data.  There is a possibility that some women in Ontario with ID were not identified using 
the algorithm and were misclassified as not having an ID.  The likelihood that the cohort 
of women without ID included a large number of women with ID is quite low given that 
ID is found in such low rates in the population.  It is possible that there are differences in 
breast cancer incidence according level severity of ID and although a relatively large 
sample of women with ID was identified, administrative data does not include 
information on severity.   
3.5.4 Implications and future research 
 The findings of this study have important implications for the detection of breast 
cancer.  The results of the present study indicate women with ID are being diagnosed 
with breast cancer at comparable rates as women without ID.  A non-significant upward 
trend was indicated by the trendline in Figure 2.  Repeating this study in future years and 
including multiple provinces would be useful to see if this pattern remains the same.  In 
addition, a larger sample size would narrow the confidence intervals of the yearly 




In Ontario, breast screening is emphasized for women 50 years of age and older; 
the data shows that screening women between 40-49 especially in women with ID, may 
be beneficial as 23% of women with ID versus only 17% in women without ID in this 
study were diagnosed within that range.  Age-specific analyses, however, did not 
demonstrate significant differences for incidence between women with and without ID in 
the 40-49 age group.  Although the finding was not statistically significant further 
research is needed to determine whether the results are clinically relevant considering the 
larger proportion of women with ID diagnosed in that age group.  Further research should 
address whether commencing breast screening earlier in women with ID is beneficial 
















 The objective of this study was to report cumulative breast cancer incidence in 
women with and without ID.  We found that yearly breast cancer incidence was 
comparable between women with and without ID.  These findings suggest women with 
ID are at no greater or lesser risk of being diagnosed with breast cancer.  Continued 
surveillance and ensuring screening and prevention strategies reach this population are 
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Background:  Breast cancer stage determines the extent to which the disease has spread 
and is an important predictor of survival.  Stage at diagnosis has not been well researched 
in women with intellectual disabilities, and to date, no population-level data is available. 
Objective:   The objectives are to describe and compare breast cancer stage at diagnosis 
between women with and without intellectual disabilities. 
Methods:  Women with and without intellectual disabilities diagnosed with breast cancer 
between 2010 and 2014 were identified using Ontario’s administrative database.  Logistic 
regression analyses were used to compare women with ID to those without, reporting the 
odds of being diagnosed at a later stage (II – IV) versus an early stage (I).   
Results:  The databases identified 91 women with ID and 29 168 women without ID 
diagnosed with breast cancer during the study period.  In the bivariate logistic regression 
women with ID were significantly more likely to be diagnosed with a later stage breast 
cancer (odds ratio1.60; 95% CI=1.03-2.48).  When adjusted for age, screening 
mammography, morbidity, and diabetes, women with ID were 1.3 times more likely to be 
diagnosed at a later stage (p=0.2).   
Conclusion: Women with intellectual disabilities were more likely to be diagnosed with 
a later stage breast cancer before adjustments for covariates.  These findings should be 
further evaluated in a larger population-level study to determine whether a significant 







4.2.1 Intellectual disability 
The American Psychiatric Association (2013) defines an intellectual disability 
(ID) as impairments in adaptive functioning and general mental abilities.  It affects 
approximately 0.8% of the Canadian population (Lunsky et al., 2013) and its symptoms 
must begin in the developmental period of life.  Diagnoses for ID are made using 
intelligence quotient (IQ) tests to measure general mental abilities as well as other 
standardized tests to determine limitations in adaptive behaviour.  Genetic, congenital or 
acquired factors alongside a variety of other reasons can cause ID (Tasman, Kay, 
Lieberman, First & Riba, 2015).  Down syndrome, fragile X syndrome and fetal alcohol 
syndrome are just a few of the conditions that are commonly associated with ID (Tasman 
et al., 2015).    
As the life expectancy of people with ID increases they are more likely to 
experience age related diseases such as breast cancer (Perkins & Moran, 2010).    
4.2.2 Breast screening 
Breast cancer screening aims to diagnose breast cancer in the early stages of 
disease progression and has been recommended for many decades (Loberg et al., 2015).  
Breast cancer screening plays a vital role in relation to stage at breast cancer diagnosis 
with mammography considered the gold standard screening tool to detect breast cancer 
(Miller, 2001).  It uses x-rays to detect and evaluate changes in the breasts and can help 
find small breast cancers when they are asymptomatic.  It is the most frequently used 
method to screen for breast cancer in women 50 -74 years of age and aims to reduce the 




Mammography screening practices are an essential tool for early detection, and in 
Ontario mammography screening services are available to all women who are eligible for 
the Ontario Health Insurance Plan (OHIP).  Ontario developed the Ontario Breast 
Screening Program (OBSP) that provides mammographic screening services to women 
50 years of age and older (Cancer Care Ontario, 2016).   Some benefits of this program 
include sending patients their screening results and recall notices when they are due for 
the next screening services, as well; a physician requisition is not required.   
Since people with ID tend be poorer, have limited literacy, and communication 
skills, they are particularly vulnerable to experiencing inequitable access to 
mammographic screening services (Willis, Kennedy & Kilbride, 2008).  For those 
individuals who rely on caregivers to assist in accessing to screening services, the 
caregiver’s attitude, knowledge and skills further influence the decision to participate in 
breast screening (Beiser & Stewart, 2005). 
Research conducted by Cobigo et al. (2013) on breast screening practices of 
Ontario women with and without ID found women with ID to be nearly twice as likely 
not to be screened for breast cancer.  The belief that women with ID are not at risk for 
breast cancer, and thus do not require screening may contribute to decreased screening 
rates found in the ID population (Cobigo et al., 2013; Ouellette-Kuntz et al., 2015).  This 
disparity may make women with ID more susceptible to being diagnosed at a later stage 
in their disease progression in comparison to women without ID.  Since women with ID 
have demonstrated decreased participation in screenings services in comparison to 





4.2.3 Cancer staging 
Cancer staging describes the extent of cancer at diagnosis and is the most 
important determinant of cancer outcomes (Warner, 2011).  Cancer is staged through the 
tumour, lymph nodes, metastasis (TNM) classification system that describes the extent 
and behaviour of tumours based on histological characteristics (Compton et al., 2012).  
Staging consists of indicating the size of the primary tumour and degree of spread, 
whether cancer has spread to nearby lymph nodes and metastasis to identify if cancer has 
spread to distant organs.  Cancer can be classified into five stages (See Appendix A, 
Table 1).  
4.2.4 Breast cancer stage at diagnosis 
 A breast cancer diagnosis is determined through the microscopic analysis of 
breast tissue (American Cancer Society, n.d.).  The breast tissue is removed from a 
suspicious area in the breast.  The tissue analysis provides a definitive diagnosis of breast 
cancer.  The breast tissue used for analysis can be obtained through either a needle or 
surgical biopsy (Schulz-Wendtland, Bautz, & Anders, 2008).  
   There is a significant lack of research in women with ID and their stage at breast 
cancer diagnosis.  Few epidemiological studies have addressed this gap, and limited 
research of any type has been performed in this area of healthcare.  The only study found 
was by Satgé et al. (2014), which reported on the breast cancer stage at diagnosis of 11 
women with ID.  The study sample was retrospectively selected from a single hospital 
including women treated for invasive breast cancer from 1989 - 2006.  The study 
reported on the tumour grade, tumour size, and disease stage at diagnosis.  Women with 




nodes, and higher tumour grades.  This study was not population based and used a small 
sample; nonetheless, this was the first study of breast cancer stage at diagnosis in women 
with ID.  This study is important because it reported on breast cancer stage at diagnosis in 
women with ID.  Our study will address some of the limitations of the study by Satgé by 
using population level data to describe breast cancer stage at diagnosis in women with 
and without ID. 
4.2.5 Significance and objectives 
Currently no quantitative population level studies have been performed that report 
on the stage at breast cancer diagnosis in women with ID. 
Evidence that women with ID have more advanced breast cancer at diagnosis than 
women without ID may be indicative of a problem with access to screening and 
diagnostic procedures.  This information would be useful to guide health care decisions 
about breast cancer management in this population, and potentially identify and address 
inequities in health service access. 
A population-based study performed in Ontario will provide locally relevant 
results on the stage at diagnosis in women with ID. 
The objectives of this research were to:  describe the stage at breast cancer 
diagnosis between women with and without ID, and compare the stage at breast cancer 






4.3.1 Study design 
This research used a cross-sectional study design to report on breast cancer stage 
at diagnosis in women with and without ID.  The cross-sectional design was common in 
studies conducted in Ontario that reported breast cancer stage at diagnosis in the general 
population (Ginsburg et al., 2015, Lipscombe et al., 2015).  This study was approved by 
the institutional review board at Sunnybrook Health Sciences Centre, Toronto, Canada 
and the University of Ontario Institute of Technology.   
4.3.2 Data sources and linkages 
In Ontario, health data collected for administrative and billing purposes are 
housed in administrative health databases.  This data is a rich source of information that 
can be used to answer a variety of research questions.  Administrative health databases 
provide researchers with historical data allowing them to study changes over time at a 
population level.  
The Institute for Clinical Evaluative Sciences (ICES) is a recognized organization 
that has secure access to large variety of administrative health data in Ontario (ICES, 
2016).  Data collected by ICES has personal identifiers removed, which are then replaced 
by a confidential ICES number (IKN).  The IKN is consistent though all administrative 
databases housed at ICES and is provided for all Ontario residents eligible for the Ontario 
Health Insurance Plan (OHIP) (ICES, 2016).  These datasets were linked using unique 




4.3.3 Data sources 
Nine administrative databases retrieved from ICES were accessed in this study 
including seven health databases, one registry and census data.  The databases were the 
Ontario Mental Health Reporting System (OMHRS), the Canadian Institute of Health 
Information Discharge Abstract Database (CIHI-DAD), the National Ambulatory Care 
Reporting System (NACRS), Same Day Surgery (SDS), OHIP, the Ontario Cancer 
Registry (OCR), Ontario Diabetes Database (ODD), the Registered Persons database 
(RPDB), and the Canadian census.  Clinical and health service data housed in these 
databases include:  mental health problems, inpatient hospital discharges, emergency 
department visits, same day surgeries, physician claims, cancer diagnoses and diabetes 
diagnoses (See Appendix B, Table 1).    
4.3.4 Study populations 
The study included two groups of women diagnosed with breast cancer.  One 
group consisted of women with ID and breast cancer; the second group included women 
without ID diagnosed with breast cancer.   
People with ID were identified from five administrative databases held at ICES 
using diagnostic codes for ID (See Appendix B, Table 2 and 3).   
The Health Care Access Research and Developmental Disabilities research 
program (H-CARDD) developed a coding algorithm to identify people with ID, which 
was used in this study (Lunsky et al., 2013).  Since ID is often diagnosed and recorded 
during childhood, the coding algorithm was applied to health databases from their date of 




detection of ID cases is a method that was evaluated and promoted by Lin et al. (2013) 
and helps to identify people with ID across all ages. 
The comparison population of Ontario females without ID was identified using 
the RPDB.  
Once both groups were identified, linkages were performed using the OCR to 
identify women newly diagnosed with invasive breast cancer (ICD-10 code: C50xx) 
between January 1, 2010 and December 31, 2014.  With permission from Cancer Care 
Ontario (CCO), information from the OCR was used to identify the breast cancer stage at 
the time of the first breast cancer diagnosis.  
Exclusion criteria 
Records of individuals with the following criteria were excluded: 
 No/invalid stage information 
 In situ (stage 0) breast cancer 
 Women with a prior cancer diagnosis 
 Women who did not have OHIP coverage in the 365 days prior to a breast cancer 
diagnosis  
 Men 
Women with in situ (stage 0) breast cancer were not included in this study to be 
consistent with previous Ontario research (Lipscombe et al., 2015; Ginsburg et al., 2015).  
It was also excluded because of the controversy surrounding the diagnosis and treatment 
of in situ breast cancer (Sakorafas, Farley & Peros, 2008).  Due to these factors this study 
focused on stage I-IV breast cancers, which are more problematic and can spread to 




4.3.5 Primary exposure, outcome and other variables 
4.3.5.1 Primary exposure 
The primary exposure variable is the presence versus absence of ID at the time of 
breast cancer diagnosis.  ID is defined as receiving a diagnosis at any point prior to 
receiving a breast cancer diagnosis.    
4.3.5.2 Primary outcome 
The primary outcome was breast cancer stage at the time of the first breast cancer 
diagnosis between 2010 and 2014, retrieved from CCO’s cancer stage data and 
categorized as stage I, II, III or IV (See Appendix A, Table 1).  Stage at breast cancer 
diagnosis was characterized as a binary variable.  Women were either diagnosed with a 
late stage breast cancer (II-IV) or at an early age (I). 
4.3.5.3 Other variables 
Demographic information on Ontario residents eligible for OHIP was retrieved 
from the RPDB.  The RPBD includes forward sortation area (FSA) data derived from the 
first three characters of postal codes (Statistics Canada, 2008).  Using the FSA, it was 
possible to determine the neighbourhood income level of individuals using the Canadian 
census.  Neighbourhood income was categorized into quintiles and provides information 
about an individual’s socioeconomic status (See Appendix B, Table 2).     
History of diabetes was obtained from the ODD and was included as a variable 
because diabetes has been associated with a later stage at breast cancer diagnosis 




The role of breast cancer screening practices was evaluated because it is one of 
the most important predictors of cancer stage at diagnosis (Taplin et al., 2004).  OBSP is 
Ontario’s organized breast screening program available for women between 50 -74 years 
of age.  Breast screening is available for all women in Ontario with no direct costs 
through OHIP claims.  Women with and without ID diagnosed with breast cancer were 
coded according to their screening practices (0=no breast cancer screen; 1=yes breast 
cancer screen).  This was done by examining data from OBSP and OHIP for bilateral 
mammography to identify those who received breast cancer screening in the 3 years to 60 
days prior to breast cancer diagnosis (Ginsburg et al., 2015).  Breast screening services 
received between 3 years and 60 days prior to breast cancer diagnosis were classified as 
screening mammograms.  To differentiate between mammograms performed as part of a 
diagnostic work up rather than screening, the methodology by Ginsburg et al. (2015) was 
followed.  A diagnostic work up is conducted when a woman presents with concerning 
signs and/or symptoms and is sent for a mammogram.  Breast screening services received 
< 60 days prior to a breast cancer diagnosis were considered pre-diagnostic 
mammograms and therefore coded as 0 (no breast screen).   
  The Adjusted Clinical Groups Case-Mix System (ACGs) developed by Johns 
Hopkins was used to determine the morbidity level for each woman using data from 
January 1, 2009 – December 31, 2014.  This system uses information on age, sex, and 
number and type of diagnoses to produce a value between 0 (non-users) and 5 (very high 
morbidity).  The Johns Hopkins group uses the term Resource Utilization Band (RUB) 




validated in Canadian populations (Reid, MacWilliam, Roos, Bogdanovic & Black, 
1999).   
 After examining the distribution of variables a decision was made to dichotomize 
them.  This was necessary due to the small cell numbers generated for some of the results 
in women with ID.  Age was categorized into < 50 and ≥ 50.  Income was grouped into 
high (quintiles 3-5) and low (quintiles (1-2).  Screening mammogram and diabetes were 
categorized as yes or no.  Lastly morbidity level was classified as either low (1-4) or high 
(5). 
4.3.6 Data analysis 
4.3.6.1 Breast cancer stage at diagnosis 
In both groups of women, stage at first breast cancer diagnosis during the study 
period was classified as stage I, II, III or IV.  Descriptive demographic information was 
provided for both cohorts including age, income quintile, screening mammography, 
prevalent diabetes, and morbidity (RUB).  
4.3.6.2 Statistical model 
Binary logistic regression analysis using the logit procedure in SAS® software 
was used to calculate crude and adjusted odds ratios (OR) (SAS Institute, 2016).  The 
primary independent variable was the presence or absence of ID, and the dependent 
variable was the odds of being diagnosed at a late stage (II-IV) versus an early stage (I) 
of breast cancer.  
An additional logistic regression analysis was performed solely on women with 
ID, reporting unadjusted and adjusted odds ratios to address the effects of the covariates 




4.3.6.3 Significance Testing 
 The significance of descriptive demographic information was evaluated using p-
values.  Two tailed z-tests for proportions were used to calculate p-values comparing 
women with and without ID.  They were also calculated using Z-test for independent 
sample means to compare mean age in women with and without ID.  P-values of less than 
0.05 were considered significant. 
 Statistical significance in the logistic regression analysis was assessed using 
confidence intervals of 95%.  Confidence intervals were used to determine the statistical 
significance between staging and covariates when comparing women with and without 
ID diagnosed at later stages.  The size of the confidence intervals is directly correlated 
with the size sample (Baptist du Prel, Hommel, Rohrig & Blettner, 2009).  Although 
confidence intervals describe a 95% probability that the true value is within the range, 
regardless of the size of the CI, the point estimate based on the data is the best estimate of 
the actual value (Baptist du Prel et al., 2009).  A significant result is demonstrated by a 















4.4.1 Baseline characteristics of women with and without ID from 2000 - 2014 
 The cohort consisted of 29, 259 women diagnosed with invasive breast cancer 
with and without ID from the Ontario female population (see Figure 1).  Within this 
group, 91 women had ID. 
Table 1 shows the baseline demographics and clinical characteristics of women 
with breast cancer (age, income quintile, prior screening behaviour, prevalent diabetes 
and morbidity).   Statistically significant differences were observed for all characteristics 
except age group.  Women with ID were evenly distributed between low and high 
income, in contrast to women without ID, where a larger proportion of women diagnosed 
with breast cancer resided in the highest income quintiles.  A greater proportion of 
women without ID received screening mammograms.  The proportion of women with ID 
with a comorbid diabetes diagnosis was greater than women without ID.  Women with ID 




















































Women with 1st breast cancer 
diagnosis in OCR January 1, 2010 to 
December 31, 2014
(n=36,784)
Women without ID with valid 
stage data
(n=29,168)
Women with ID with valid stage 
data
(n=91)
Excluded women  aged <30 or >105 at 
diagnosis date (n=501)
Exculded women with previous cancer 
in the OCR (n=5,635)
Exclude lymphoma cases (n=<6)
Exculde women with missing income 
(n=115)
Excluded women not eligibile for OHIP in 
the 365 days prior to breast cancer 
diagnosis (n=488)
Excluded women with invalid/no stage 
information or stage in situ (0) (n=785)
Women with breast cancer 
eligible for the study 
(n= 29,259)
Figure 1. 
Study populations of women with and without ID diagnosed 








Characteristics of women with and without ID diagnosed with breast cancer (N=29,259) 
(Ontario, 2010-2014) 
 
  Total with ID Total without ID P- valuea 
 N=91 N= 29, 168 
Age 
Mean ± SD 57.10 ± 11.8 60.58 ± 13.3 p < 0.05b 
Age group 
<50 27 (29.7%) 6,458 (22.1%) p > 0.05 
≥ 50 64 (70.3%)  22,710 (77.9%) 
 
p > 0.05 
Neighbourhood income quintile 
1-2 45 (49.5%) 10,676 (36.6%) p < 0.05 
3-5 46 (50.5%) 18,492 (63.3%) p < 0.05 
Screening mammogram 
Yes 38 (41.8%) 16,042 (55.0%) 
 
p < 0.05 
No 53 (58.2%) 13,126 (45.0%) 
Previous Diagnosis of Diabetes 
Yes 30 (33.0%) 5,011 (17.2%) 
 
p < 0.05 
No 61 (67.0%) 24,157 (82.8%) 
Morbidity Level (RUB) 
1-4 23 (25.3%) 10,561 (36.2%) 
 
p < 0.05 
5 68 (74.7%) 18,607 (63.8%) 
 
p < 0.05 
a According to the two tailed Z test for proportions 





4.4.2 Breast cancer stage at diagnosis in women with and without ID 
Table 2 shows the baseline characteristics of women with late versus early stage 
breast cancer.  Significant differences were observed for all baseline characteristics 
except for morbidity level.  A greater proportion of women younger than 50 were 
diagnosed with a later stage breast cancer, while the opposite was true for women 50 
years of age and older.  For both women with early and late stage breast cancer a larger 
proportion of them resided in the highest income quintiles.  The majority of women 
(70%) diagnosed with stage I breast cancer had a screening mammogram prior to being 
diagnosed in comparison with only 43% of women diagnosed with a late stage breast 
cancer.  In both early and late stage breast cancers, the majority of women (≅64%) 
resided in the highest morbidity categories. 
Figure 2 demonstrates the proportions of women with and without ID diagnosed 
with breast cancer by stage at diagnosis.  The greatest proportion of women with ID were 
diagnosed with stage II breast cancer (46%), while in women without ID the majority 
were diagnosed at stage I (44%).   This figure demonstrates a greater proportion of 
women with ID (67%) were diagnosed with a later stage breast cancer when compared to 
women without ID (60%).  When comparing stage IV breast cancer, the results showed 
8% of women with ID were diagnosed at the latest stage versus only 4% in women 
without ID. 
4.4.3 Regression analysis results 
Women with ID were significantly more likely to present with a later stage breast 
cancer (II-IV) than women without ID when unadjusted odds ratios were calculated (see 




III or IV breast cancer was 1.6 times (p<0.05) larger than women without ID.  Once the 
odds ratio was adjusted for the covariates, women with ID were no longer significantly 
more likely to be diagnosed with late stage breast cancer (OR 1.3, p = 0.2).  
A successive regression analysis was performed on the cohort of women with ID 
to address the effect of the covariates on a late stage breast cancer.  The results are 
described in Table 4, where non-significant differences in the effects of each covariate 

































Characteristics of women with early and late stage breast cancer (N=29,259) (Ontario, 
2010-2014) 
 
 Stage I Stage II-IV P- valuea 
 N = 12,865 N = 16, 394 
Age group 
< 50 2,037 (15.8%) 4,448 (27.1%) p < 0.05 
≥ 50 10,828 (84.2%) 11,946 (72.9%) p < 0.05 
Neighbourhood income quintile 
1-2 4,551 (35.4%) 6,170 (37.6%) p < 0.05 
3-5 8,314 (64.6%) 10,224 (62.4%) p < 0.05 
Screening mammogram 
Yes 8,994 (69.9%) 7,086 (43.2%) p < 0.05 
No 3,871 (30.1%) 9,308 (56.8%) p < 0.05 
Previous diabetes 
Yes 2,115 (16.4%) 2,926 (17.8%) p < 0.05 
No 10,750 (83.6%) 13,468 (82.2%) p < 0.05 
Morbidity level 
1-4 4,663 (36.2%) 5,921 (36.1%) p > 0.05 
5 8,202 (63.8%) 10,473 (63.9%) p > 0.05 
























Logistic regression results estimating the unadjusted and adjusted odds ratio for late stage 









ORa 95% CIb OR 95% CIb 
ID status 
(ID vs. No ID) 1.60 
1.03 – 2.48 
 
1.33 0.85 – 2.11 
Age 
(<50 versus ≥50) 1.98 




(low (quintile 1+2) 
vs. high (quintile 
≥3)) 
1.10 1.05 - 1.16 1.04 0.99-1.10 
Screening 
mammogram  





2.70 - 2.98 
 
Morbidity 
(high RUBc (5) vs. 
low RUB (1-4)) 
1.01 0.96-1.06 1.11 
1.05 - 1.16 
 
Diabetes  
(Yes vs. No) 1.10 
1.04 – 1.17 
 
1.16 1.09-1.24 
a OR:  odds ratio 
b 95% CI:  95% confidence interval 














Logistic regression results estimating the unadjusted and adjusted odds ratio for advanced 








ORa 95% CIb ORa 95% CIb 
Age 
(<50 versus ≥50) 2.82 0.95-8.42 1.64 0.51-5.55 
Income quintile 
(low (quintile 1+2) 
vs. high (quintile 
≥3)) 
1.18 0.49-2.83 1.13 0.44-2.90 
Screening 
mammogram  
(No vs. Yes) 
3.08 1.24 -7.60 2.53 0.97-6.62 
Morbidity 
(high RUBc (5) vs. 
low RUB (1-4)) 
4.39 1.18-16.22 3.68 0.94-14.35 
Diabetes  
(Yes vs. No) 1.28 0.51-3.21 1.019 0.38-2.76 
a OR:  odds ratio 
b 95% CI:  95% confidence interval 






4.5.1 Summary of results 
 This is the only population study of breast cancer stage at diagnosis in women 
with ID.  The objective was to report and compare breast cancer stage at diagnosis in 
women with and without ID.  Of the 29, 259 women diagnosed with invasive breast 
cancer, 91 women had an ID.   The majority of women with ID were diagnosed with 
stage II breast cancer; in contrast, the majority of women without ID were diagnosed at 
stage I.  A logistic regression analysis was performed to determine the odds of women 
with ID being diagnosed at a late (II-IV) versus early (I) stage breast cancer.   The 
unadjusted odds ratio showed that, compared to women without ID, women with ID were 
significantly more likely to be diagnosed at a later stage.  When adjusted for covariates 
(age, income quintile, screening mammogram, morbidity and prevalent diabetes) 
however, the odds ratio comparing the two groups of women was not statistically 
significant.  
4.5.2 Results in context of past research 
Significant differences were noted in the mean ages at diagnosis between both 
groups of women.  Women with ID were diagnosed at a mean age of 57 and women 
without ID were diagnosed at a mean age of 61.  Prior research conducted in France 
found the mean ages to be 56 in women with ID and 62 in women without ID (Satgé et 
al., 2014).  However, an Australian study by Sullivan et al. (2003) found the mean age at 
diagnosis to be 49 in women with ID.  The lower age at diagnosis found in the Australian 
study may be due to its inclusion criteria that allowed for younger women in the sample 




demonstrated that women with ID are diagnosed at a younger age in comparison to 
women without ID.  The age specific breast cancer incidence calculations performed in 
manuscript 1, demonstrated that the differences in age can be accounted for by the 
difference in the age distributions between women with and without ID. 
Overall, women in this study were predominantly diagnosed with stage I or II 
breast cancer.  The majority of women with ID were diagnosed with stage II breast 
cancer, while the majority of women without ID were diagnosed with stage I breast 
cancer.  The only other study to look at stage at diagnosis in women with ID was a small 
hospital based study conducted by Satgé et al. (2014).  In accordance with the present 
study, Satgé found that the largest proportion of women with ID were diagnosed at stage 
II.  In the present study, the proportion of women with ID diagnosed with stage II breast 
cancer was 46%, while Satgé found the proportion to be 73%.  Though there is a 
discrepancy in the results, our finding is likely more accurate owing to our larger sample 
size (n=91 vs. Satgé n=11).  
In an unadjusted odds ratio comparing women with and without ID, women with 
ID were significantly more likely to be diagnosed with a late stage breast cancer. These 
results are again consistent with the research by Satgé et al. (2014).  The French study 
found a significant unadjusted odds ratio of 3.2 representing the risk of being diagnosed 
with stage II versus stage I and an odds ratio of 10.2 comparing Stage III versus stage I.  
This is considerably higher than the present study with an of 1.6 comparing stage II-IV 
versus stage I.  Both studies demonstrated that women with ID are at an increased risk of 
being diagnosed with a later stage breast cancer. The study by Satgé also reported on 




greater tumour sizes and were more likely to have metastases and lymph node 
involvement.  
Although Satgé found that women with ID were more likely to be diagnosed at 
later stage, significant differences were not noted in the histologically types of breast 
cancer.  Thus women with ID were not diagnosed with more aggressive cancers.  
Histology was not assessed in the present study since women with ID are very 
heterogeneous and different syndromes may present with different physiological 
differences.  Thus the focus remained on health service access issues and their association 
with stage at diagnosis. 
Prior population level research on other minority and vulnerable populations have 
demonstrated an increased risk of being diagnosed with a later stage breast cancer.  An 
Ontario study by Ginsburg et al. (2015) found that South Asian women had a significant 
adjusted odds ratio of 1.3 comparing stage II-IV to stage I breast cancer.  In the United 
States (USA), researchers found some visible minorities (Black, South Asian & Hispanic) 
were at a greater risk of presenting with a later stage breast cancer relative to non-
Hispanic whites (Li, Malone &Daling, 2003; Iqbal, Ginsburg, Rochon, Sun & Narod, 
2015; Warner et al., 2012).  The odds ratios in the studies ranged from 1.25-3.6, 
demonstrating that minority and vulnerable populations are at a greater risk of being 
diagnosed at a later stage.  The magnitudes of the odds ratios in some of the 
aforementioned studies are comparable with that of the present study (Li et al., 2015; 
Ginsburg et al., 2015).  It is possible that some minority and vulnerable populations are 




  Though it was not our primary objective, it was instructive to look at other 
variables strongly associated with late stage breast cancers.  Breast screening plays an 
integral role in relation to breast cancer stage at diagnosis (Miller, 2001) and, of all the 
covariates in this study, it showed the strongest association with the outcome:  women 
were close to 3 times more likely to be diagnosed with a later stage breast cancer if they 
did not participate in routine screening.  
In addition, the current study found that women with ID were less likely to have 
obtained a screening mammogram.  This is consistent with previous research that found 
that women with ID are less likely to participate in breast screening when compared to 
women without ID (Cobigo et al., 2013; Sullivan et al., 2001).  For instance, Cobigo et al. 
(2013) demonstrated that less than 50% of Ontario women with ID participated in breast 
screening.  Screening practices may be lower in women with ID due to challenges 
associated with their disability.  It may be technically challenging to perform optimal 
mammograms exacerbated by communication challenges and possible comorbid physical 
disabilities.  Decreased screening among Ontario women generally, and in women with 
ID specifically, contribute to their likelihood of receiving a later stage diagnosis; 
however, women with ID are starting at a lower screening take-up rate and at least 
matching the rate in the general population would lead to more equity in terms of health 
service access and potential outcomes.  The results of this study have demonstrated that 
more attention needs to be given to women with ID so that earlier diagnoses can be 
achieved. 
Among all women, screening practices, high morbidity, and the prevalence of 




influence of these risk factors contributed to why women with ID were diagnosed at a 
later stage as can be seen in the changes in crude to adjusted odds ratios for the primary 
independent variable.  There was a decrease in the unadjusted odds ratio from 1.6 to 1.3 
when comparing women with and without ID after controlling for other variables.  This 
suggests that the associations found between the covariates (i.e. age, income quintile, 
breast screening practices, morbidity and diabetes) and breast cancer stage at diagnosis 
can explain some of the variation in staging between women with and without ID.  In our 
opinion, an adjusted odds ratio of 1.3 still suggests that having an ID is an independent 
predictor of late stage breast cancer diagnosis, but the lack of statistical power due to the 
low number of women with ID in the sample resulted in a non-significant result.  This 
finding needs to be corroborated with a larger sample, an issue dealt with in the limitation 
section of this manuscript.   
Additional analyses were performed solely on women with ID in order to identify 
potential factors associated with being diagnosed at a later stage.  There was a consistent 
pattern between the model with all women and the model among only those with ID in 
that the odds ratios for all of the covariates were very comparable, except for morbidity.  
The morbidity variable, however may have been largely influenced by a small cell size 
among women with ID with low morbidity used in the odds ratio calculation.  Overall, 
these results demonstrate that the factors that result in all women being diagnosed at a 
later stage are consistent with those that affect women with ID alone.  Thus, factors 
including preventive and early detection initiatives that are addressed in women without 





4.5.3 Strengths and limitations 
 Population level data was used to identify women with and without ID diagnosed 
with breast cancer and their stage at diagnosis.  Considering only about 1% of the 
population has ID, administrative data allowed us to identify a relatively large number of 
women with ID diagnosed with breast cancer (Lunsky et al., 2013).  
 This study has several limitations.  There is a possibility that the algorithm did not 
identify some women with ID, resulting in a misclassification error.  Previous research 
has found that women with milder disabilities are probably underrepresented, as they are 
more likely to go unidentified in administrative databases (Iezzoni, 2002).  It is not 
uncommon for people with mild ID to go undiagnosed since they often function 
reasonably well in society (British Institute of Learning Disabilities, n.d.; Thambirajah, 
2007).  In addition due to the limitations of administrative data, we were unable to 
identify the severity of the ID which is a potentially important risk factor.  Although the 
data was adjusted for a variety of covariates that influence breast cancer stage, this study 
did not include other factors such as family history of breast cancer, and lifestyle factors.   
After adjusting for covariates, this study did not find a statistically significant 
difference between women with and without ID regarding breast cancer stage. This may 
be the result of type II error (i.e. failing to reject the null hypothesis that is false, also 
known as a false negative).  A post hoc power analysis found the power of this study to 
be 0.59; thus, there was a 41% chance of type II error in this study.  A power of 59% is 
less than the standard 80% power that is considered adequate to report a difference when 




primary independent variable and outcome when examining the crude odds ratio and this 
is possibly due to type II error.  
4.5.4 Implications and future research 
This study is important because, it demonstrates that women with ID are 
significantly more likely to be diagnosed with a later stage breast cancer (before 
adjustments with covariates).  Prior research on minority and vulnerable populations 
demonstrated significant results with odds ratios comparable to the present study.  A 
study of stage at diagnosis in women with ID across all or multiple provinces would be 
beneficial to increase the amount of women with ID in the study sample.  A larger study 
would increase the statistical power and potentially provide more conclusive results on 
the risk of being diagnosed at a later stage.   
The covariates that contribute to being diagnosed with breast cancer at a later 
stage are, being < 50, not participating in regular screening, having a high morbidity, and 
prevalent of diabetes.  Greater proportions of women with ID were found in all of those 
covariates when compared to women without ID. 
In Ontario, women are encouraged to begin breast screening at 50 (Cancer Care 
Ontario, 2015b).  This threshold may not be beneficial for women with ID, as 30% of 
them in this study were diagnosed before the age of 50.  Large population studies are 
required to further establish whether having ID is an independent predictor for advanced 
stage breast cancer and to establish benefits of identifying them as high risk.  
The lower breast screening usage in women with ID highlights the need for 
improved access and utilization of breast screening services, seeing as it is the greatest 




disability, as women with comorbid physical disabilities are not easily accommodated by 
mammography.  In addition to the technical challenges, women with ID may have 
difficulty understanding the procedure.  
Standard recruitment strategies may not be suitable for women with ID and self-
referral is unlikely unless they are encouraged by an advocate or family member 
(Sullivan, Slack-Smith & Hussain, 2004).  Since women with ID often have limited 
knowledge about breast cancer, further research is needed to identify whether using 
patient navigators could be a useful tool for women with ID to provide individualized 
assistance and facilitate timely access breast screening services (Dohan & Schrag, 2005; 
Natale-Pereira, Enard, Nevarez & Jones, 2011).  Navigators can be used to help increase 
compliance with breast screening services.  The support of a patient navigator may help 
decrease anxiety associated with medical examinations and increase patient satisfaction.  
Patient navigators would prepare the women for the exam by empowering them and 
providing emotional and informational support (Dohan & Schrag, 2005; Fowler, 
Steakley, Garcia, Kwok & Bennett, 2006; Marriott, Turner, Ashby & Rees, 2015; Meade 
et al., 2014).  They can help bridge the gap between health care professionals and women 
with ID as communication can often be challenging (Dohan & Schrag, 2005; Marriott et 
al., 2015; Mcilfatrick, Taggart & Truesdale-Kennedy, 2011; Meade et al., 2014; Natale-
Pereira et al., 2011).  Patient navigators may be a very useful tool to help reduce 
disparities and improve the uptake of mammographic screening in women with ID.  It is 
imperative that further research is performed in this area to identify if implementing 




Caregivers need to  be properly educated and supported as they play an integral 
role in the health of people with ID (Krahn et al., 2006).  It is important that caregivers 
understand the importance of breast screening and early detection in women with ID as 
their attitude and knowledge greatly influence participation in secondary prevention 
strategies (Lunsky et al., 2013).  Thus it is not only important to empower the patient but 
also the caregiver as women with ID often heavily rely on them to help navigate through 
the healthcare system.  They can be used independently or in addition to patient 
navigators to help support people with ID. 
 It is essential that research be performed to identify barriers that restrict access to 
breast screening for women with ID to help improve the number of women who actively 
participate in breast screening.  Reducing barriers to breast screening services should in 
turn contribute to a reduction in women with ID being diagnosed with breast cancer at a 














 Our study found that ID was associated with later breast cancer stage at diagnosis 
when considering the unadjusted odds ratio. When adjusted for covariates, women with 
ID were no longer more likely to be diagnosed at a later stage, suggesting some of the 
variation in stage between both groups was explained through the associations found 
between the covariates and breast cancer staging. The lack of statistical significance for 
the multivariate results in this study was possibly due to type II error.  The small sample 
of women with ID and breast cancer resulted in a lack of power to detect an effect where 
one may exist.  Therefore, larger population-level studies are needed to evaluate whether 
































































5.1 Thesis Conclusion 
5.1.1 Introduction 
Women with ID have impairments in both general mental abilities and adaptive 
functioning (American Psychiatric Association, 2013).  They are more disadvantaged and 
are more likely to be diagnosed with various health conditions (Lunsky et al., 2013).  
Women with ID have higher morbidity when compared to women without ID (Lunsky et 
al., 2013).  Previous research has demonstrated that the life expectancy of people with ID 
is increasing in parallel to those without ID (Bittles et al., 2002; Emerson & Baines, 
2011; Kapell, et al., 1998; Perkins & Moran, 2010).  Their increased life expectancy 
increases the likelihood that they will be diagnosed with an age related health concern 
such as cancer.  In women, breast cancer is a significant contributor to the morbidity and 
mortality of the general population (Canadian Cancer Statistics, 2016).  However, breast 
cancer has not been well studied in women with ID and its impact is not well understood.  
As the life expectancy of women with ID increases, it becomes increasingly important to 
identify if any disparities exist between women with and without ID in relation to breast 
cancer.   
5.1.2 Summary of results 
Manuscript 1 addressed the first objective:  To describe and compare breast 
cancer incidence in women with and without ID.  Using administrative databases women 
with and without ID diagnosed with breast cancer between 2000 and 2014 were 
identified.  When compared to women without ID, a greater proportion of women with 
ID were diagnosed with breast cancer at < 50.  Women without ID diagnosed with breast 




proportion of women with ID resided in the lowest income quintile. Yearly cumulative 
breast cancer incidence was calculated and no statistical difference was found between 
the two cohorts after adjusting for age.  Thus, the present study did not demonstrate any 
disparities in breast cancer incidence between women with and without ID. 
Manuscript 2 addressed the second objective:  To describe and compare breast 
cancer stage at diagnosis in women with and without ID.  Women diagnosed with breast 
cancer were classified as having either an early (I) or late stage (II-IV) cancer.  
Administrative databases were used to identify women with and without ID diagnosed 
with breast cancer between 2010 and 2014 and their stage at diagnosis.  The largest 
proportion of women with ID were diagnosed with breast cancer at stage II, in contrast to 
women without ID who were predominately diagnosed at stage I.   Unadjusted and 
adjusted odds ratios were calculated to determine the odds of being diagnosed at a later 
stage if you have an ID vs. no ID.  Adjusted odds ratios addressed the effect of the 
covariates on being diagnosed at a later stage.  Women with ID were significantly more 
likely to be diagnosed at a later stage before adjustments for covariates.  Adjusted odds 
ratios demonstrated women with ID were not significantly more likely to be diagnosed at 
a later stage. 
5.1.3 Future research 
 This thesis made a significant contribution the body of Canadian research on the 
health of women with ID.  No prior Canadian research had been performed to identify 
and compare breast cancer incidence and stage at diagnosis between women with and 




cancer incidence in both populations is comparable but disparities may be present as 
women with ID may be diagnosed at later stages when compared to women without ID.   
 The model of healthcare disparities and disability described in this thesis is a 
multi-faceted tool that recognized the importance of environmental and personal factors 
and how their interactions can affect the health status of people with ID.  Unfortunately, 
in this research, environmental factors could not be studied due to the limitations inherent 
in the use of administrative data.  In the context of this research environmental factors 
could include, physical, social and attitudinal factors.  
 Important differences in breast cancer staging were not detected due to the small 
sample.  Larger population studies including multiple provinces would make it possible 
to determine whether a significant difference is present in stage at diagnosis between 
women with and without ID.  
 Prior and current research have highlighted the need for improved access and 
utilization of breast screening services in women with ID.  It is essential that future 
research be performed to identify barriers that restrict access to breast screening services 
in women with ID to improve utilization.  
 Lastly, we recommend future research on other cancers, specifically those with 
screening programs in place, to identify any disparities in the incidence of various 
cancers as well as the stage at diagnosis between people with and without ID.          
5.1.4 Conclusion 
 In conclusion, this thesis found that the incidence of breast cancer was 
comparable between women with and without ID.  This finding demonstrates that women 




compared to women without ID.  Although they are being diagnosed at comparable rates, 
disparities may exist within the stage at diagnosis.  Women with ID were significantly 
more likely to be diagnosed at a later stage in an unadjusted odds ratio, nonetheless when 
adjusted for covariates the finding was not significant.  The findings of this research fill a 
gap in the literature, as stage at diagnosis had never been studied in women with ID at the 
population level.  This study recommends a larger population study be performed to 
confirm whether significant differences are observed between women with and without 
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Table 1:  Tumour, lymph node and metastasis (TNM) Classification – Breast Cancer 
 
Stage Definition 
Stage 0 Breast cancer in situ 
o Tumour confined to original site 
o Non-invasive 
Stage 1 Invasive breast cancer 
o Small cancer (<2mm) or tumour (< 2cm) 
o No lymph node involvement or spread to other organs 
Stage II  Invasive breast cancer 
o Cancers (>2mm) with lymph node involvement (1-3 nodes) 
OR 
o Tumour (<2cm) with lymph node involvement  (1-3 nodes) 
OR 
o Tumour (2cm < tumour < 5cm) with lymph node 
involvement 
OR 
o Tumour (>5cm) with no lymph node involvement 
Stage III Invasive breast cancer 
o Cancer with 4-9 lymph nodes 
OR 
o Tumour (>5cm) with lymph node involvement (1-3 nodes) 
OR with cancer cells found in the lymph nodes ( 0.2mm< 
cancer <2mm) 
Stage IV Invasive breast cancer 












Table 1:  Administrative databases housed at the Institute for Clinical Evaluative 
Sciences 
Administrative database Definition 
Ontario Mental Health Reporting 
System (OMHRS) 
Contains data about mental health 
conditions 
Canadian Institute for Health 
Information-Discharge Abstract 
Database (CIHI-DAD) 
Contains administrative, clinical and 
demographic data on inpatient hospital 
discharges 
National Ambulatory Care Reporting 
System (NACRS) 
Contains data on emergency room visits 
Same Day Surgery (SDS) Contains data on day surgery visits 
The Ontario Health Insurance Plan 
(OHIP) 
Contains data on physician claims for 
insured services provided to residents of 
Ontario 
Registered Persons Database (RPDB) Contains demographic information on 
Ontario residents eligible for health 
insurance coverage 
Ontario Cancer Registry (OCR) Contains data on cancer diagnoses 
including data on stage at diagnosis 
Canadian Census Contains demographic data such as postal 
codes  
Ontario Diabetes Database Contains data on diabetes diagnoses 
 
 
Ontario Breast Screening Program 
Database 
























Discharges with any 
diagnosis listed in Table 
3 
 
 In any diagnostic field 
 For all facilities 
submitting to DAD, SDS 
and NACRS 
 From inception of 






















 Q3 = 1 
 Or Q2aa, Q2ab or 
Q2ac in 299 to 
299.80 
 Or Q2b in 317 to 
319.99 
 Or l11a-l11f = any 
diagnosis of Qxxx as 
listed in Table 3 
 
 For all facilities 
submitting to OMHRS 
 From inception of 









 For all providers 
submitting to OHIP 
 From June 1991 – 




Table 3:  Codes associated with intellectual disability codes in the International 




299-299.99 Pervasive developmental disorders 
317-317.99 Mental Retardation 
318-318.99 Mental Retardation 
319-319.99 Mental Retardation 
758.0-
758.39 




Other conditions due to chromosome anomalies (do not include 758.81) 
758.9 Conditions due to anomaly of unspecified chromosome 
759.5 Tuberous sclerosis 
759.81 Other and unspecified congenital anomalies:  Prader-Willi syndrome 
759.821 Other and unspecified congenital anomalies:  de Lange syndrome 
759.827 Other and unspecified congenital anomalies:  Seckel syndrome 
759.828 Other and unspecified congenital anomalies:  Smith-Lemli-Opitz 
syndrome 
759.83 Other and unspecified congenital anomalies:  Fragile X syndrome 
759.874 Other and unspecified congenital anomalies:  Beckwith-Wiedemann 
syndrome 
759.875 Other and unspecified congenital anomalies:  Zellweger syndrome 
759.89 Other and unspecified congenital anomalies: other 
760.71 Fetal alcohol syndrome 
760.77 Fetal hydantoin syndrome 
ICD-10    
F700 Mild mental retardation with the statement of no, or minimal, 
impairment of behaviour 
F701 Mild mental retardation, significant impairment of behaviour requiring 
attention or treatment 
F708 Mild mental retardation, other impairments of behaviour 
F709 Mild mental retardation without mention of impairment of behaviour 
F710 Moderate mental retardation with the statement of no, or minimal, 
impairment of behaviour 
F711 Moderate mental retardation, significant impairment of behaviour 
requiring attention or treatment 
F718 Moderate mental retardation, other impairments of behaviour 





F720 Severe mental retardation with the statement of no, or minimal, 
impairment of behaviour 
F721 Severe mental retardation, significant impairment of behaviour 
requiring attention or treatment 
F728 Severe mental retardation, other impairments of behaviour 
F729 Severe mental retardation without mention of impairment of 
behaviour 
F730 Profound mental retardation with the statement of no, or minimal, 
impairment of behaviour 
F731 Profound mental retardation, significant impairment of behaviour 
requiring attention or treatment 
F738 Profound mental retardation, other impairments of behaviour 
F739 Profound mental retardation without mention of impairment of 
behaviour 
F780 Other mental retardation with the statement of no, or minimal, 
impairment of behaviour 
F781 Other mental retardation, significant impairment of behaviour 
requiring attention or treatment 
F788 Other mental retardation, other impairments of behaviour 
F789 Other mental retardation without mention of impairment of behaviour 
F790 Unspecified mental retardation with the statement of no, or minimal, 
impairment of behaviour 
F791 Unspecified mental retardation, significant impairment of behaviour 
requiring attention or treatment 
F798 Unspecified mental retardation, other impairments of behaviour 
F799 Unspecified mental retardation without mention of impairment of 
behaviour 
F840 Childhood autism 
F841 Atypical autism 
F843 Other childhood disintegrative disorder 
F844 Overactive disorder associated with mental retardation and 
stereotyped movements 
F845 Asperger’s syndrome 
F848 Other pervasive developmental disorders 
F849 Pervasive development disorder, unspecified 
Q851 Tuberous sclerosis 
Q860 Fetal alcohol syndrome 
Q861 Fetal hydantoin syndrome 
Q871 Aarskog, Prader-Willi, deLange, Seckel, etc. 
Q8723 Rubinstein-Taybi syndrome 
Q8731 Sotos syndrome 
Q878 Other 
Q900-Q939 All Down syndrome types 
Q971 Female with more than three X chromosomes 




Q998 Other specified chromosome abnormalities 
 
Figure 3. Developmental disabilities and related codes included in the International Classification 
of Diseases, 9th and 10th editions. Reprinted from the “ Atlas on the primary care of adults with 
developmental disabilities in Ontario,” by Y. Lunsky, J.E. Klein-Geltink and E.A. Yates, 2013, 
Retrieved from 
https://www.camh.ca/en/research/news_and_publications/reports_and_books/Documents/HCAR





























Table 1:  Relevance of the studies included in the literature review 
Literature Review 
Title Summary 
Incidence of breast cancer in the general population 
Retrospective Cohort Studies 




Country:  Canada 
Breast cancer is the most diagnosed 
cancer in Canadian women.  Following 
fluctuations in breast cancer incidence, 
since 2004 the incidence of breast cancer 
has stabilized.  
Kachuri, L., De, P., Ellison, L. F., 
Semenciw, R. (2013) 
 
Cancer incidence, mortality and survival 
trends in Canada, 1970 – 2007 
 
Country:  Canada 
The study reported cancer incidence in 
Canada.  The incidence of breast cancer 
in Canada rose between 1970 and 1988 
at a rate of 0.9% yearly.  After which it 
began to decline at a rate of 0.7% yearly. 
Australian Institute of Health and Welfare. 
(2013) 
 
Cancer in Australia:  Actual incidence data 
from 1991 to 2009 and mortality data from 
19991 to 2010 with projections to 2012 
 
Country:  Australia 
This study used Australian databases to 
report on cancer incidence between 1991 
and 2010.  After an increase in breast 
cancer incidence between 1991 and 
1995, incidence rates stabilized. 
Molinié, F., Vanier, A., Woronoff, A. S., 
Guizard, A. V., Delafosse, P., Velten, M., . 
. . Tretarre, B. (2014) 
 
Trends in breast cancer incidence and 
mortality in France 1990-2008.  
 
Population level French registries were 
used to report on the incidence of breast 
cancer between 1990 and 2008.  From 
1990 – 2003 the incidence of breast 





Country:  France 
Kohler, B. A., Sherman, R. L., Howlader, 
N., Jemal, A., Ryerson, A. B., Henry, K. 
A., . . . Penberthy, L. (2015) 
 
Annual Report to the Nation on the Status 
of Cancer, 1975-2011, Featuring Incidence 
of Breast Cancer Subtypes by 
Race/Ethnicity, Poverty, and State. 
 
Country:  United States of America 
Using population level data acquired 
from registries, the study reported that 
the incidence of breast cancer remained 
stable between 2002 and 2011 
Summary of studies on the incidence of breast cancer in the general population 
All of the abovementioned studies employed a retrospective cohort methodology 
using administrate databases or registries to report on breast cancer trends over time.   
All the studies demonstrated that the incidence of breast cancer has stabilized.  This 
suggests that in the present study I should see a stable trend of breast cancer incidence 
in the general population in accordance with the above studies.  The studies were 
useful to inform the methods used in the present study. 
 
Incidence of breast cancer in subpopulations 
Retrospective Cohort Studies 
 
Marrett, L. D., & Chaudhry, M. (2003) 
 
Cancer incidence and mortality in Ontario 






Country:  Canada 
The study reported on cancer incidence 
and mortality amongst Ontario First 
Nations (FN) people from 1968 – 1991 
in comparison to the Ontario population.  
Women registered under the Indian act 
were identified and linked to the Ontario 
Cancer Registry.  The results 
demonstrated breast cancer incidence in 
First Nations people was significantly 
lower when compared with the general 
population.  The reduced rate of breast 
cancer may be attributed to a 
combination of both FN women 




younger age and having more children 
than women in the general population. 
Ali, R., Barnes, I., Kan, S. W., & Beral, V. 
(2010) 
 
Cancer incidence in British Indians and 
British whites in Leicester, 2001-2006.  
 
Country:  England 
Both cancer registries and hospital 
databases were used to identify cases of 
breast cancer in British Indians and 
British whites.  The incidence of breast 
cancer was lower in British Indians 
when compared to British whites.  
Boehmer, U., Miao, X., Maxwell, N. I., & 
Ozonoff, A. (2014) 
 
Sexual minority population density and 
incidence of lung, colorectal and female 
breast cancer in California. 
 
Country:  United States of America 
Survey data linked with the California 
Cancer registry identified sexual 
minorities (gay, lesbian, bisexual) with 
incident lung, colorectal and breast 
cancer.  The study revealed two 
associations.  Lesbians had a higher 
incidence of breast cancer, whereas 
being bisexual was associated with a 
lower incidence of breast cancer. 
Summary of studies on the incidence of breast cancer in subpopulations 
The studies on subpopulations used a consistent methodology.  The studies used either 
registry or survey data to identify the subpopulation.  Once identified the 
subpopulations were linked to cancer registries to identify incident breast cancers.  A 
limitation of reporting on subpopulations is the potential for misclassification error.  
These studies informed my research as they used consistent methodologies of 
identifying subpopulations and linking them to cancer registries. 
Incidence of breast cancer in people with intellectual disabilities 




Patja, K., Eero, P., & Iivanainen, M. 
(2001) 
 
Cancer incidence among people with 
intellectual disability 
 
Country:  Finland 
People with ID were identified using a 
nation-wide survey administered to the 
Finnish population.  Once identified they 
were linked to the Finish cancer registry 
to identify incident cancers in the study 
period.  The incidence of breast cancer 
in people with and without ID was 
comparable. 
Sullivan, S. G., Glasson, E. J., Hussain, R., 
Petterson, B. A., Slack-Smith, L. M., 
Montgomery, P. D., & Bittles, A. H. 
(2003) 
 
Breast cancer and the uptake of 
mammography screening services by 
women with intellectual disabilities 
 
Country:  Australia 
The Disability Services Commission of 
Western Australia was used to identify 
people with ID.  Once identified they 
were linked to the Western Australia 
Cancer Registry.  This study found the 
incidence of breast cancer to be lower in 
the ID population. 
 
Janicki, M. P., Dalton, A. J., Henderson, 
C. M., & Davidson, P. W. (1999) 
 
Mortality and morbidity among older 
adults with intellectual disability: health 
services considerations 
 
Country:  United States of America 
The study reported on mortality and 
morbidity in people with ID 40 and older 
who died between 1984 -1993.  The 
main causes of death in people with ID 
were cardiovascular, respiratory and 
neoplastic disease.  Although this study 
does not report on breast cancer 
incidence it demonstrated the trend that 
the life expectancy of people with ID is 
increasing. 





As people with intellectual disabilities are living longer into the age group of people 
being diagnosed with breast cancer, it is important to understand the impact in that 
population.  The above studies used different methods to identify people with 
intellectual disabilities (e.g. survey, database).  Once identified they were linked to 
cancer registries to determine incident breast cancer.  These studies informed my 
research as they have conflicting results on the incidence of breast cancer in people 
with ID.  The limitations of both the study by Patja and Sullivan are the small sample 
sizes, which limit the power of the study to make statistically significant observations. 
Breast cancer stage at diagnosis in the general population 
Retrospective Cohort Studies 
 
 
Anderson, W. F., Reiner, A. S., Matsuno, 
R. K., & Pfeiffer, R. M. (2007) 
 





Country:  United States of America 
This study examined five decades of 
breast cancer incidence, rates and age 
distributions.  A 110% increase was 
observed in the incidence rates of early 
stage tumours between 1973 and 2003.  
A 2.9% decrease was observed in the 
incidence rates of late stage tumours.  
The mean age during the entire study 
period for women diagnosed at an early 
stage was 44 and for women diagnosed 
at later stages was 73. 
 
Henley, S. J., King, J. B., German, R. R., 
Richardson, L. C., & Plescia, M. (2010) 
 
Surveillance of screening-detected cancers 
(colon and rectum, breast, and cervix) - 
United States, 2004-2006 
 
 
Country:  United States of America 
Data acquired from registries and 
databases were used to determine the 
incidence rates for late-stage cancers.  
The study population was restricted to 
women between the ages of 50 – 74.  
The incidence of late stage breast 
cancers was lowest among women 50 – 
59 and highest among women 60 – 79 
years of age.  Between 2004 and 2006 
one third of breast cancers were 
diagnosed at a late stage where treatment 




McPhail, S., Johnson, S., Greenberg, D., 
Peake, M., & Rous, B. (2015) 
 
Stage at diagnosis and early mortality from 
cancer in England 
 
Country:  England 
An English study reported stage at 
diagnosis of breast, colon, lung, prostate 
and ovarian cancer in 2012 using 
administrative data.  The majority of 
participants presented at either stage I or 
II breast cancer.   
Summary of studies on breast cancer stage at diagnosis in the general population 
These studies were valuable as they demonstrated that the majority of cancers in the 
general population are diagnosed at earlier stages.  As well the study by Anderson 
demonstrated an important shift to younger ages at diagnosis.  This stresses the 
importance of including women under the age of 50 in my study. 
Breast cancer stage at diagnosis in subpopulations 
Retrospective Cohort Studies 
 
Newman, L. A., & Alfonso, A. E. (1997) 
 
Age-related differences in breast cancer 
stage at diagnosis between black and white 
patients in an urban community hospital 
 
 
Country:  United States of America 
Retrospective reviews of hospital and 
physician records paired with cancer 
registry data were used to determine the 
age and stage at diagnosis in black and 
white patients.  Black patients were 
significantly more likely to be diagnosed 
at a younger age and a more advanced 
stage.  The mean age at diagnosis for 
black patients was 56, while the mean 
age for white patients was 63.     
Deshpande, A. D., Jeffe, D. B., Gnerlich, 
J., Iqbal, A. Z., Thummalakunta, A., & 
Margenthaler, J. A. (2009). 
 
Racial disparities in breast cancer survival: 
an analysis by age and stage 
 
Country:  United States of America 
Administrative data was used to identify 
the study cohorts of Black and White 
women diagnosed with breast cancer.  
During the study period of 1988 – 2003, 
Black women were more likely to be 
diagnosed at more advanced stages when 
compared to White women.  They were 
also more likely to be diagnosed with 




Hensley Alford, S., Schwartz, K., Soliman, 
A., Johnson, C. C., Gruber, S. B., & 
Merajver, S. D. (2009) 
 
Breast cancer characteristics at diagnosis 
and survival among Arab-American 
women compared to European- and 
African-American women 
 
Country:  United States of America 
This study compared breast cancer in 
Arab, White and Black women.  Arab 
women were identified in a registry 
using a name algorithm.  The overall 
mean age at diagnosis was 60 and the 
majority of breast cancer cases were 
diagnosed at a local stage.  Both Black 
and Arab women were more likely to be 
diagnosed at a younger age and a more 
advanced stage of cancer.  
Cross Sectional Studies 
 
 
Ginsburg, O. M., Fischer, H. D., Shah, B. 
R., Lipscombe, L., Fu, L., Anderson, G. 
M., & Rochon, P. A. (2015) 
 
A population-based study of ethnicity and 





Country:  Canada 
This study examined the association 
between ethnicity and stage at diagnosis.  
The ethnicities studied were Chinese and 
South Asian women compared to the 
general population.  Using Ontario’s 
cancer registry all women diagnosed 
with breast cancer between 2005 and 
2010 were identified.  Surname 
algorithms were used to specifically 
identify Chinese and South Asian 
women.  South Asian were more likely 
to be diagnosed at a later stage, while 
Chinese women were more likely to be 
diagnosed at an earlier stage. 
Lipscombe, L. L., Fischer, H. D., Austin, 
P. C., Fu, L., Jaakkimainen, R. L., 
Ginsburg, O., . . . Paszat, L. (2015) 
 
The association between diabetes and 
breast cancer stage at diagnosis: a 
population-based study 
 
Country:  Canada 
This Ontario study used administrative 
data to compare women with and 
without diabetes and their breast cancer 
stage at diagnosis.  The results 
demonstrated that the majority of women 
were diagnosed at either stage I or II.  
Nonetheless women with diabetes were 
significantly more likely to be diagnosed 
at a more advanced stage. 




The studies demonstrated that some visible minorities (Black, South Asian, Arab) are 
more likely to be diagnosed at a later stage when compared to the general population. 
 
Both cross sectional studies performed in Ontario using administrative databases 
informed the methodology used in manuscript 2.  A cross sectional design was 
implemented to be consistent with prior Ontario research.  The studies by Ginsburg 
and Lipscombe demonstrated how administrative databases could be used to identify 
subpopulations, which can be further linked to the Ontario Cancer Registry.     
Cancer stage at diagnosis in people with intellectual disabilities 
Prospective Qualitative Study 
 
Tuffrey-Wijne, I., Bernal, J., Hubert, J., 
Butler, G., & Hollins, S. (2009) 
 
People with learning disabilities who have 





Country:  England 
The goal of this study was to provide 
awareness about the needs and 
experiences of people with ID that have 
a cancer diagnosis through participant 
observation.  This study explored the 
impact of cancer, their experience of 
care and barriers to healthcare access.  
The mean age of participants was 53 
years.  Although in the majority of cases 
people with ID were diagnosed at late 
stages, the types of cancer were not 
included. 
Case Control 
Satgé, D., Sauleau, E. A., Jacot, W., Raffi, 
F., Azéma, B., Bouyat, J. C., & El Hage 
Assaf, N. (2014) 
 
Age and stage at diagnosis:  a hospital 
series of 11 women with intellectual 
disability and breast carcinoma 
 
 
Country:  France 
This study provided detailed information 
about 11 female patients with ID 
diagnosed with breast cancer.  The study 
assessed histology, tumour grade, age, 
tumour size and disease stage at 
diagnosis.  The study found that the 
mean age of diagnosis within the ID 
sample was 55.64 whilst in the non-
disabled population the mean age at 
diagnosis was 62.35.  In an unadjusted 
OR women with ID had a 3.2 times 




and 10.2 times higher risk of being 
diagnosed with stage III.  The study 
showed that women with ID had larger 
tumours at diagnosis; lymph node 
involvement and blood metastases were 
more frequent. 
Summary of cancer stage at diagnosis in people with intellectual disabilities 
The prospective qualitative study informed my research as the results showed the 
majority of people with ID in their study were diagnosed at late stages.  The study by 
Satgé was the sole study found focused on breast cancer stage at diagnosis in women 
with intellectual disabilities.  The limitation of the studies was that they were not 
population based and few patients were included.  The findings were not 
representative of the populations of interest. 
 
